Therapeutic Compounds Useful for the Prophylactic or Therapeutic Treatment of an HIV Virus Infection CROSS REFERENCE TO RELATED APPLICATIONS [0001] This application claims the benefit of U.S. Provisional Application No. 63/357,859, filed on July 1, 2022, the entire content of which is hereby incorporated by reference in its entirety. TECHNICAL FIELD [0002] The present disclosure provides compounds and salts thereof, and compositions, which are useful in the prevention and/or treatment of HIV. BACKGROUND [0003] The HIV/AIDS pandemic has claimed the lives of millions of people, and millions more are currently infected. Antiretroviral therapy has turned HIV infection into a chronic, manageable disease; however, no cure yet exists for HIV. Patients must remain on therapy for their whole lives making drug resistance an ongoing issue. Additionally, as patients age, concomitant treatment for other diseases and conditions becomes more common, increasing the potential for drug-drug interactions with HIV antiviral treatment. Accordingly, continued development of new antiviral drugs and combination therapies are a priority in the field of HIV therapeutics. [0004] Positive-single stranded RNA viruses comprising the Retroviridae family include those of the subfamily Orthoretrovirinae and genera Alpharetrovirus, Betaretrovirus, Gammaretrovirus, Deltaretrovirus, Epsilonretrovirus, Lentivirus, and Spumavirus which cause many human and animal diseases. Among the Lentivirus, HIV-1 infection in humans leads to depletion of T helper cells and immune dysfunction, producing immunodeficiency and vulnerability to opportunistic infections. Treating HIV-1 infections with highly active antiretroviral therapies (HAART) has proven to be effective at reducing viral load and significantly delaying disease progression (Hammer, S.M., et al.; JAMA 2008, 300: 555-570). However, these treatments could lead to the emergence of HIV strains that are resistant to current therapies (Taiwo, B., International Journal of Infectious Diseases 2009, 13:552-559; new antiretroviral agents that are active against emerging drug-resistant HIV variants. [0005] In view of widespread HIV infection and the challenges in overcoming drug resistances and drug-drug interactions, there is a continuing need for new and improved antiviral agents. The compounds disclosed herein, as well as their compositions and methods of use described herein, are directed toward fulfilling this need. SUMMARY [0006] The present disclosure provides a compound selected from the compound of Formula I, the compound of Formula II, the compound of Formula III, the compound of Formula IV, the compound of Formula V, and the compound of Formula VI:

[0007] The present disclosure further provides compositions comprising a compound of the disclosure, or pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier. [0008] The present disclosure further provides preparations comprising a compound of the disclosure, or a pharmaceutically acceptable salt thereof. [0009] The present disclosure further provides methods of preventing or treating an HIV infection in a human by administering to the human a therapeutically effective amount of a compound of the disclosure, or a pharmaceutically acceptable salt thereof. DETAILED DESCRIPTION I. Compounds [0010] The present disclosure is directed to certain compounds, and uses thereof. [0011] As used herein, the term “lenacapavir” refers to the compound N-((S)-1-(3-(4- chloro-3-(methylsulfonamido)-1-(2,2,2-trifluoroethyl)-1H-ind azol-7-yl)-6-(3-methyl-3- (methylsulfonyl)but-1-yn-1-yl)pyridin-2-yl)-2-(3,5-difluorop henyl)ethyl)-2-((3bS,4aR)-5,5- difluoro-3-(trifluoromethyl)-3b,4,4a,5-tetrahydro-1H-cyclopr opa[3,4]cyclopenta[1,2-c]pyrazol- 1-yl)acetamide, having the following structure:

[0012] In some embodiments, the compound of the disclosure is selected from the compound of Formula 1, the compound of Formula II, the compound of Formula 111, the compound of Formula IV, the compound of Formula V, and the compound of Formula VI:

or a pharmaceutical [0013] In some embodiments, the compound is a compound of Formula I, or a salt thereof. In some embodiments, the compound is a compound of Formula I, or a pharmaceutically acceptable salt thereof. [0014] In some embodiments, the compound is a compound of Formula II, or a salt thereof. In some embodiments, the compound is a compound of Formula II, or a pharmaceutically acceptable salt thereof. [0015] In some embodiments, the compound is a compound of Formula III, or a salt thereof. In some embodiments, the compound is a compound of Formula III, or a pharmaceutically acceptable salt thereof. [0016] In some embodiments, the compound is a compound of Formula IV, or a salt thereof. In some embodiments, the compound is a compound of Formula IV, or a pharmaceutically acceptable salt thereof. [0017] In some embodiments, the compound is a compound of Formula V, or a salt thereof. In some embodiments, the compound is a compound of Formula V, or a pharmaceutically acceptable salt thereof. [0018] In some embodiments, the compound is a compound of Formula VI, or a salt thereof. In some embodiments, the compound is a compound of Formula VI, or a pharmaceutically acceptable salt thereof. [0019] The present disclosure further includes salts of the compounds of the disclosure, such as pharmaceutically acceptable salts. A salt generally refers to a derivative of a disclosed compound wherein the parent compound is modified by converting an existing acid or base moiety to its salt form. A pharmaceutically acceptable salt is one that, within the scope of sound medical judgment, is suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio. Examples of pharmaceutically acceptable salts include, but are not limited to, mineral or organic acid salts of basic residues such as amines; alkali or organic salts of acidic residues such as carboxylic acids; and the like. The pharmaceutically acceptable salts of the present disclosure include the conventional non-toxic salts of the parent compound formed, for example, from non-toxic inorganic or organic acids. The pharmaceutically acceptable salts of the present disclosure can be synthesized from the parent compound which contains a basic or acidic moiety by conventional chemical methods. Generally, such salts can be prepared by reacting the free acid or base forms of these compounds with a stoichiometric amount of the appropriate base or acid. Lists of suitable salts are found in Remington’s Pharmaceutical Sciences, 17 ^th ed., Mack Publishing Company, Easton, Pa., 1985, p. 1418 and Journal of Pharmaceutical Science, 66, 2 (1977), each of which is incorporated herein by reference in its entirety. In some embodiments, the pharmaceutically acceptable salt is a sodium salt.

[0020] In some embodiments, the compounds of Formulas I- VI, or pharmaceutically acceptable salts thereof, are substantially isolated. By “substantially isolated” is meant that the compound, or salt thereof, is at least partially or substantially separated from the environment in which it was formed or detected. Partial separation can include, for example, a composition enriched in the compound of the disclosure. Substantial separation can include compositions containing at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, at least about 95%, at least about 97%, or at least about 99% by weight of the compound, or a pharmaceutically acceptable salt thereof. In some embodiments, the compound of Formula I, or a pharmaceutically acceptable salt thereof, is substantially isolated. In some embodiments, the compound of Formula II, or a pharmaceutically acceptable salt thereof, is substantially isolated. In some embodiments, the compound of Formula III, or a pharmaceutically acceptable salt thereof, is substantially isolated. In some embodiments, the compound of Formula IV, or a pharmaceutically acceptable salt thereof, is substantially isolated. In some embodiments, the compound of Formula V, or a pharmaceutically acceptable salt thereof, is substantially isolated. In some embodiments, the compound of Formula VI, or a pharmaceutically acceptable salt thereof, is substantially isolated.

[0021] The compounds of the disclosure, or pharmaceutically acceptable salts thereof, can be present in a composition, wherein the composition includes at least one compound other than the compound of the disclosure (i.e., a compound of Formulas I- VI). In some embodiments, the composition includes more than one compound of the disclosure. In some embodiments, the composition comprises one or more compounds of the disclosure, or pharmaceutically acceptable salts thereof, and lenacapavir, or a pharmaceutically acceptable salt thereof. Compositions can be mixtures containing a compound of the disclosure, or pharmaceutically acceptable salt thereof, and one or more solvents, substrates, carriers, etc. In some embodiments, the composition comprises a compound of the disclosure, or pharmaceutically acceptable salt thereof, in an amount greater than about 25% by weight. In some embodiments, the composition comprises a compound of the disclosure, or pharmaceutically acceptable salt thereof, in an amount greater than about 50% by weight. In some embodiments, the composition comprises a compound of the disclosure, or pharmaceutically acceptable salt thereof, in an amount greater than about 75% by weight. In some embodiments, the composition comprises a compound of the disclosure, or pharmaceutically acceptable salt thereof, in an amount greater than about 80% by weight. In some embodiments, the composition comprises a compound of the disclosure, or pharmaceutically acceptable salt thereof, in an amount greater than about 85% by weight. In some embodiments, the composition comprises a compound of the disclosure, or pharmaceutically acceptable salt thereof, in an amount greater than about 90% by weight. In some embodiments, the composition comprises a compound of the disclosure, or pharmaceutically acceptable salt thereof, in an amount greater than about 95% by weight.

[0022] In some embodiments, the composition comprises a compound of the disclosure, or pharmaceutically acceptable salt thereof, in an amount less than about 25% by weight. In some embodiments, the composition comprises a compound of the disclosure, or pharmaceutically acceptable salt thereof, in an amount less than about 20% by weight. In some embodiments, the composition comprises a compound of the disclosure, or pharmaceutically acceptable salt thereof, in an amount less than about 15% by weight. In some embodiments, the composition comprises a compound of the disclosure, or pharmaceutically acceptable salt thereof, in an amount less than about 10% by weight. In some embodiments, the composition comprises a compound of the disclosure, or s pharmaceutically acceptable alt thereof, in an amount less than about 5% by weight. In some embodiments, the composition comprises a compound of the disclosure, or pharmaceutically acceptable salt thereof, in an amount less than about 1% by weight. In some embodiments, the composition comprises a compound of the disclosure, or pharmaceutically acceptable salt thereof, in an amount less than about 0.5% by weight. In some embodiments, the composition comprises a compound of the disclosure, or pharmaceutically acceptable salt thereof, in an amount less than about 0.1% by weight. In some embodiments, the composition comprises a compound of the disclosure, or pharmaceutically acceptable salt thereof, in an amount less than about 0.05% by weight. In some embodiments, the composition comprises a compound of the disclosure, or pharmaceutically acceptable salt thereof, in an amount less than about 0.01% by weight.

[0023] A preparation of a compound of the disclosure, or pharmaceutically acceptable salt thereof, can be prepared by chemical synthesis or by isolation of the compound from a biological sample. Preparations can have a purity of greater than about 50%, greater than about 60%, greater than about 70%, greater than about 80%, greater than about 90%, or greater than about 95% purity. Purity can be measured by any of conventional means, such as by chromatographic methods or spectroscopic methods like NMR, MS, LC-MS, etc.

[0024] In some embodiments, the preparation of a compound of the disclosure, or a pharmaceutically acceptable salt thereof, has greater than about 50% purity. In some embodiments, the preparation of a compound of the disclosure, or a pharmaceutically acceptable salt thereof, has greater than about 60% purity. In some embodiments, the preparation of a compound of the disclosure, or a pharmaceutically acceptable salt thereof, has greater than about 70% purity. In some embodiments, the preparation of a compound of the disclosure, or a pharmaceutically acceptable salt thereof, has greater than about 80% purity. In some embodiments, the preparation of a compound of the disclosure, or a pharmaceutically acceptable salt thereof, has greater than about 90% purity. In some embodiments, the preparation of a compound of the disclosure, or a pharmaceutically acceptable salt thereof, has greater than about 95% purity.

[0025] The compounds of the disclosure are asymmetric ( e.g., having one or more stereocenters). All stereoisomers, such as enantiomers and diastereomers, are intended unless otherwise indicated. Methods on how to prepare optically active forms from optically active starting materials are known in the art, such as by resolution of racemic mixtures or by stereoselective synthesis.

[0026] The compounds of the disclosure also include all isotopes of atoms occurring in the compounds. Isotopes include those atoms having the same atomic number but different mass numbers. For example, isotopes of hydrogen include tritium and deuterium. In some embodiments, the compound includes at least one deuterium. It is understood by one skilled in the art that this disclosure also includes any compound claimed that may be enriched at any or all atoms above naturally occurring isotopic ratios with one or more isotopes such as, but not limited to, deuterium ( ² H or D). As a non-limiting example, in certain embodiments, a -CH3 group is replaced with -CD3.

[0027] The term, “compound”, as used herein, is meant to include all stereoisomers, geometric isomers, tautomers, and isotopes of the structures depicted.

II. Compositions

[0028] The present disclosure further includes a pharmaceutical composition comprising a compound of the disclosure, or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier. As used herein, “pharmaceutically acceptable carrier” is meant to refer to any adjuvant, carrier, excipient, glidant, sweetening agent, diluent, preservative, dye/colorant, flavor enhancer, surfactant, wetting agent, dispersing agent, suspending agent, stabilizer, isotonic agent, solvent, or emulsifier which has been approved by the United States Food and Drug Administration as being acceptable for use in humans or domestic animals.

[0029] In some embodiments, the pharmaceutical composition comprising a compound of the disclosure, or a pharmaceutically acceptable salt thereof, further comprises one, two, three, or four additional therapeutic agents.

[0030] In some embodiments, the one, two, three, or four additional therapeutic agents is selected from the group consisting of combination drugs for HIV, other drugs for treating HIV, HIV protease inhibitors, HIV non-nucleoside or non-nucleotide inhibitors of reverse transcriptase, HIV nucleoside or nucleotide inhibitors of reverse transcriptase, HIV integrase inhibitors, HIV non-catalytic site (or allosteric) integrase inhibitors, HIV entry inhibitors, HIV maturation inhibitors, HIV capsid inhibitors, nucleocapsid protein 7 (NCp7) inhibitors, HIV Tat or Rev inhibitors, inhibitors of Tat-TAR-P-TEFb, immunomodulators, immunotherapeutic agents, antibody-drug conjugates, gene modifiers, gene editors (such as CRISPR/Cas9, zinc finger nucleases, homing nucleases, synthetic nucleases, TALENs), cell therapies (such as chimeric antigen receptor T-cell, CAR-T, and engineered T-cell receptors, TCR-T, autologous T-cell therapies, engineered B cells, NK cells), latency reversing agents, immune-based therapies, phosphatidylinositol 3-kinase (PI3K) inhibitors, HIV antibodies, bispecific antibodies and “antibody-like” therapeutic proteins, HIV p!7 matrix protein inhibitors, IL-13 antagonists, peptidyl-prolyl cis-trans isomerase A modulators, protein disulfide isomerase inhibitors, complement C5a receptor antagonists, DNA methyltransferase inhibitor, Fatty acid synthase inhibitor, HIV vif gene modulators, Vif dimerization antagonists, HIV-1 viral infectivity factor inhibitors, HIV-1 Nef modulators, TNF alpha ligand inhibitors, HIV Nef inhibitors, Hck tyrosine kinase modulators, mixed lineage kinase-3 (MLK-3) inhibitors, HIV-1 splicing inhibitors, integrin antagonists, nucleoprotein inhibitors, splicing factor modulators, COMM domain containing protein 1 modulators, HIV ribonuclease H inhibitors, IFN antagonists, retrocyclin modulators, CD3 antagonists, CDK-4 inhibitors, CDK-6 inhibitors, CDK-9 inhibitors, Cytochrome P450 3 inhibitors, CXCR4 modulators, dendritic ICAM-3 grabbing nonintegrin 1 inhibitors, HIV GAG protein inhibitors, HIV POL protein inhibitors, Complement Factor H modulators, ubiquitin ligase inhibitors, deoxycytidine kinase inhibitors, cyclin dependent kinase inhibitors, HPK1 (MAP4K1) inhibitors, proprotein convertase PC9 stimulators, ATP dependent RNA helicase DDX3X inhibitors, reverse transcriptase priming complex inhibitors, G6PD and NADH-oxidase inhibitors, mTOR complex 1 inhibitors, mTOR complex 2 inhibitors, P-Glycoprotein modulators, RNA polymerase modulators, TAT protein inhibitors, Prolyl endopeptidase inhibitors, Phospholipase A2 inhibitors, pharmacokinetic enhancers, HIV gene therapy, HIV vaccines, and anti-HIV peptides, or any combinations thereof.

[0031] In some embodiments, the one, two, three, or four additional therapeutic agents is selected from the group consisting of combination drugs for HIV, other drugs for treating HIV, HIV protease inhibitors, HIV reverse transcriptase inhibitors, HIV integrase inhibitors, HIV non-catalytic site (or allosteric) integrase inhibitors, HIV entry (fusion) inhibitors, HIV maturation inhibitors, latency reversing agents, capsid inhibitors, immune-based therapies, PI3K inhibitors, HIV antibodies, bispecific antibodies, “antibody-like” therapeutic proteins, or any combinations thereof. [0032] In some embodiments, the one, two, three, or four additional therapeutic agents is selected from the group consisting of dolutegravir, cabotegravir, darunavir, bictegravir, elsulfavirine, rilpivirine, abacavir sulfate, tenofovir, tenofovir disoproxil, tenofovir disoproxil fumarate, tenofovir disoproxil hemifumarate, tenofovir alafenamide, and tenofovir alafenamide hemifumarate, or a pharmaceutically acceptable salt thereof.

[0033] Except as expressly defined otherwise, the present disclosure includes all tautomers of compounds detailed herein, even if only one tautomer is expressly represented (e.g., both tautomeric forms are intended and described by the presentation of one tautomeric form where a pair of two tautomers may exist). For example, if reference is made to a compound containing an amide (e.g., by structure or chemical name), it is understood that the corresponding imidic acid tautomer is included by this disclosure and described the same as if the amide were expressly recited either alone or together with the imidic acid. Where more than two tautomers may exist, the present disclosure includes all such tautomers even if only a single tautomeric form is depicted by chemical name and/or structure.

[0034] The pharmaceutical compositions disclosed herein can be prepared by methodologies well known in the pharmaceutical art. For example, in certain embodiments, a pharmaceutical composition intended to be administered by injection can prepared by combining a compound of the disclosure with sterile, distilled water so as to form a solution. In some embodiments, a surfactant is added to facilitate the formation of a homogeneous solution or suspension. Surfactants are compounds that non-covalently interact with the compound of the disclosure so as to facilitate dissolution or homogeneous suspension of the compound in the aqueous delivery system.

[0035] Administration of the compounds of the disclosure, or their pharmaceutically acceptable salts, can be carried out via any of the accepted modes of administration of agents for serving similar utilities. The pharmaceutical compositions of the disclosure can be prepared by combining a compound of the disclosure, or a pharmaceutically acceptable salt thereof, with an appropriate pharmaceutically acceptable carrier and, in specific embodiments, are formulated into preparations in solid, semi solid, liquid or gaseous forms, such as tablets, capsules, powders, granules, ointments, solutions, suppositories, injections, inhalants, gels, microspheres, and aerosols. Exemplary routes of administering such pharmaceutical compositions include, without limitation, oral, topical, transdermal, inhalation, parenteral, sublingual, buccal, rectal, vaginal, and intranasal. In a particular embodiment, pharmaceutical compositions of the disclosure are tablets. In another embodiment, pharmaceutical compositions of the disclosure are injection (intramuscular (IM) or intraperitoneal (IP)). Pharmaceutical compositions of the disclosure are formulated so as to allow the active ingredients contained therein to be bioavailable upon administration of the composition to a patient. Compositions that will be administered to a subject or patient take the form of one or more dosage units, where for example, a tablet may be a single dosage unit, and a container of a compound of the disclosure in aerosol form may hold a plurality of dosage units. Actual methods of preparing such dosage forms are known, or will be apparent, to those skilled in this art; for example, see Remington: The Science and Practice of Pharmacy, 20th Edition (Philadelphia College of Pharmacy and Science, 2000). The composition to be administered will, in any event, contain a therapeutically effective amount of a compound of the disclosure, or a pharmaceutically acceptable salt thereof, for treatment of a disease or condition of interest in accordance with the teachings described herein.

[0036] The compounds of the disclosure, or their pharmaceutically acceptable salts, can be administered in a therapeutically effective amount, which will vary depending upon a variety of factors including the activity of the specific compound employed; the metabolic stability and length of action of the compound; the age, body weight, general health, sex, and diet of the patient; the mode and time of administration; the rate of excretion; the drug combination; the severity of the particular disorder or condition; and the subject undergoing therapy.

[0037] The disclosure will be described in greater detail by way of specific examples. The following examples are offered for illustrative purposes, and are not intended to limit the disclosure in any manner. Those of skill in the art will readily recognize a variety of noncritical parameters which can be changed or modified to yield essentially the same results.

III. Methods

[0038] The present disclosure further relates to a method of treating or preventing an HIV infection (e.g., HIV-1 and/or HIV-2) in a patient (e.g., a human patient) by administering to the patient a therapeutically effective amount of a compound of the disclosure (e.g. , a compound of any of Formulas I- VI), or a pharmaceutically acceptable salt thereof. The patient may have or be at risk of having the infection (e.g. , a patient who has one or more risk factors known to be associated with contracting the HIV virus). [0039] In some embodiments, the current disclosure provides a method of treating a Retroviridae viral infection, including an infection caused by the HIV virus, in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of a compound of the disclosure, or a pharmaceutically acceptable salt thereof.

[0040] In some embodiments, the current disclosure provides a method of preventing or treating an HIV infection in a human comprising administering to the human a therapeutically effective amount of a compound of the disclosure, or a pharmaceutically acceptable salt thereof.

[0041] In some embodiments, the current disclosure provides a method of treating an HIV infection in a patient, comprising administering to the patient a therapeutically effective amount of a compound of the disclosure, or a pharmaceutically acceptable salt thereof.

[0042] In some embodiments, the current disclosure provides a method of preventing an HIV infection in a subject, comprising administering to the patient a therapeutically effective amount of a compound of the disclosure, or a pharmaceutically acceptable salt thereof. In some embodiments, the compounds disclosed herein are used for preventing an HIV infection in a subject at risk for infection. In some embodiments, the compounds disclosed herein are used for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1.

[0043] In some embodiments, the methods disclosed herein further comprise administering to the human a therapeutically effective amount of one, two, three, or four additional therapeutic agents.

[0044] In some embodiments, the one, two, three, or four additional therapeutic agents is selected from the group consisting of combination drugs for HIV, other drugs for treating HIV, HIV protease inhibitors, HIV non-nucleoside or non-nucleotide inhibitors of reverse transcriptase, HIV nucleoside or nucleotide inhibitors of reverse transcriptase, HIV integrase inhibitors, HIV non-catalytic site (or allosteric) integrase inhibitors, HIV entry inhibitors, HIV maturation inhibitors, HIV capsid inhibitors, nucleocapsid protein 7 (NCp7) inhibitors, HIV Tat or Rev inhibitors, inhibitors of Tat-TAR-P-TEFb, immunomodulators, immunotherapeutic agents, antibody-drug conjugates, gene modifiers, gene editors (such as CRISPR/Cas9, zinc finger nucleases, homing nucleases, synthetic nucleases, TALENs), cell therapies (such as chimeric antigen receptor T-cell, CAR-T, and engineered T-cell receptors, TCR-T, autologous T-cell therapies, engineered B cells, NK cells), latency reversing agents, immune-based therapies, phosphatidylinositol 3-kinase (PI3K) inhibitors, HIV antibodies, bispecific antibodies and “antibody-like” therapeutic proteins, HIV p!7 matrix protein inhibitors, IL-13 antagonists, peptidyl-prolyl cis-trans isomerase A modulators, protein disulfide isomerase inhibitors, complement C5a receptor antagonists, DNA methyltransferase inhibitor, Fatty acid synthase inhibitor, HIV vif gene modulators, Vif dimerization antagonists, HIV-1 viral infectivity factor inhibitors, HIV-1 Nef modulators, TNF alpha ligand inhibitors, HIV Nef inhibitors, Hck tyrosine kinase modulators, mixed lineage kinase-3 (MLK-3) inhibitors, HIV-1 splicing inhibitors, integrin antagonists, nucleoprotein inhibitors, splicing factor modulators, COMM domain containing protein 1 modulators, HIV ribonuclease H inhibitors, IFN antagonists, retrocyclin modulators, CD3 antagonists, CDK-4 inhibitors, CDK-6 inhibitors, CDK-9 inhibitors, Cytochrome P450 3 inhibitors, CXCR4 modulators, dendritic ICAM-3 grabbing nonintegrin 1 inhibitors, HIV GAG protein inhibitors, HIV POL protein inhibitors, Complement Factor H modulators, ubiquitin ligase inhibitors, deoxycytidine kinase inhibitors, cyclin dependent kinase inhibitors, HPK1 (MAP4K1) inhibitors, proprotein convertase PC9 stimulators, ATP dependent RNA helicase DDX3X inhibitors, reverse transcriptase priming complex inhibitors, G6PD and NADH-oxidase inhibitors, mTOR complex 1 inhibitors, mTOR complex 2 inhibitors, P-Glycoprotein modulators, RNA polymerase modulators, TAT protein inhibitors, Prolyl endopeptidase inhibitors, Phospholipase A2 inhibitors, pharmacokinetic enhancers, HIV gene therapy, HIV vaccines, and anti-HIV peptides, or any combinations thereof.

[0045] In some embodiments, the one, two, three, or four additional therapeutic agents is selected from the group consisting of combination drugs for HIV, other drugs for treating HIV, HIV protease inhibitors, HIV reverse transcriptase inhibitors, HIV integrase inhibitors, HIV non-catalytic site (or allosteric) integrase inhibitors, HIV entry (fusion) inhibitors, HIV maturation inhibitors, latency reversing agents, capsid inhibitors, immune-based therapies, PI3K inhibitors, HIV antibodies, bispecific antibodies, “antibody-like” therapeutic proteins, or any combinations thereof.

[0046] In some embodiments, the one, two, three, or four additional therapeutic agents is selected from the group consisting of dolutegravir, cabotegravir, darunavir, bictegravir, elsulfavirine, rilpivirine, abacavir sulfate, tenofovir, tenofovir disoproxil, tenofovir disoproxil fumarate, tenofovir disoproxil hemifumarate, tenofovir alafenamide, and tenofovir alafenamide hemifumarate, or a pharmaceutically acceptable salt thereof. [0047] In some embodiments, provided herein is a compound disclosed herein, or a pharmaceutically acceptable salt thereof, for use in preventing or treating an HIV infection in a human.

[0048] In some embodiments, the use provided herein further comprises administering to the human a therapeutically effective amount of one, two, three, or four additional therapeutic agents.

[0049] In some embodiments of the uses provided herein, the one, two, three, or four additional therapeutic agents is selected from the group consisting of combination drugs for HIV, other drugs for treating HIV, HIV protease inhibitors, HIV non-nucleoside or nonnucleotide inhibitors of reverse transcriptase, HIV nucleoside or nucleotide inhibitors of reverse transcriptase, HIV integrase inhibitors, HIV non-catalytic site (or allosteric) integrase inhibitors, HIV entry inhibitors, HIV maturation inhibitors, HIV capsid inhibitors, nucleocapsid protein 7 (NCp7) inhibitors, HIV Tat or Rev inhibitors, inhibitors of Tat-TAR-P-TEFb, immunomodulators, immunotherapeutic agents, antibody-drug conjugates, gene modifiers, gene editors (such as CRISPR/Cas9, zinc finger nucleases, homing nucleases, synthetic nucleases, TALENs), cell therapies (such as chimeric antigen receptor T-cell, CAR-T, and engineered T- cell receptors, TCR-T, autologous T-cell therapies, engineered B cells, NK cells), latency reversing agents, immune-based therapies, phosphatidylinositol 3-kinase (PI3K) inhibitors, HIV antibodies, bispecific antibodies and “antibody-like” therapeutic proteins, HIV pl7 matrix protein inhibitors, IL- 13 antagonists, peptidyl-prolyl cis-trans isomerase A modulators, protein disulfide isomerase inhibitors, complement C5a receptor antagonists, DNA methyltransferase inhibitor, Fatty acid synthase inhibitor, HIV vif gene modulators, Vif dimerization antagonists, HIV-1 viral infectivity factor inhibitors, HIV-1 Nef modulators, TNF alpha ligand inhibitors, HIV Nef inhibitors, Hck tyrosine kinase modulators, mixed lineage kinase-3 (MLK-3) inhibitors, HIV-1 splicing inhibitors, integrin antagonists, nucleoprotein inhibitors, splicing factor modulators, COMM domain containing protein 1 modulators, HIV ribonuclease H inhibitors, IFN antagonists, retrocyclin modulators, CD3 antagonists, CDK-4 inhibitors, CDK-6 inhibitors, CDK-9 inhibitors, Cytochrome P450 3 inhibitors, CXCR4 modulators, dendritic ICAM-3 grabbing nonintegrin 1 inhibitors, HIV GAG protein inhibitors, HIV POL protein inhibitors, Complement Factor H modulators, ubiquitin ligase inhibitors, deoxycytidine kinase inhibitors, cyclin dependent kinase inhibitors, HPK1 (MAP4K1) inhibitors, proprotein convertase PC9 stimulators, ATP dependent RNA helicase DDX3X inhibitors, reverse transcriptase priming complex inhibitors, G6PD and NADH-oxidase inhibitors, mTOR complex 1 inhibitors, mTOR complex 2 inhibitors, P-Glycoprotein modulators, RNA polymerase modulators, TAT protein inhibitors, Prolyl endopeptidase inhibitors, Phospholipase A2 inhibitors, pharmacokinetic enhancers, HIV gene therapy, HIV vaccines, and anti-HIV peptides, or any combinations thereof.

[0050] In some embodiments of the uses provided herein, the one, two, three, or four additional therapeutic agents is selected from the group consisting of combination drugs for HIV, other drugs for treating HIV, HIV protease inhibitors, HIV reverse transcriptase inhibitors, HIV integrase inhibitors, HIV non-catalytic site (or allosteric) integrase inhibitors, HIV entry (fusion) inhibitors, HIV maturation inhibitors, latency reversing agents, capsid inhibitors, immune-based therapies, PI3K inhibitors, HIV antibodies, bispecific antibodies, “antibody-like” therapeutic proteins, or any combinations thereof.

[0051] In some embodiments of the uses provided herein, the one, two, three, or four additional therapeutic agents is selected from the group consisting of dolutegravir, cabotegravir, darunavir, bictegravir, elsulfavirine, rilpivirine, abacavir sulfate, tenofovir, tenofovir disoproxil, tenofovir disoproxil fumarate, tenofovir disoproxil hemifumarate, tenofovir alafenamide, and tenofovir alafenamide hemifumarate, or a pharmaceutically acceptable salt thereof.

[0052] In some embodiments, the current disclosure provides a method for inhibiting the replication of the HIV virus, treating AIDS, or delaying the onset of AIDS in a patient (<?.g., a human), comprising administering to the patient a compound of the disclosure, or a pharmaceutically acceptable salt thereof. [0053] In certain embodiments, a compound of the disclosure (i.e. a compound of

Formula I, II, III, IV, V, and/or VI) or a pharmaceutically acceptable salt thereof, for use in the manufacture of a medicament for treating an HIV infection or the replication of the HIV virus or AIDS or delaying the onset of AIDS in a subject (e.g., a human) is disclosed. One embodiment relates to a compound of Formula I, II, III, IV, V, and/or VI, or a pharmaceutically acceptable salt thereof, for use in the prophylactic or therapeutic treatment of an HIV infection or AIDS or for use in the therapeutic treatment or delaying the onset of AIDS.

[0054] In some embodiments, the use of a compound of Formula I, II, III, IV, V, and/or VI, or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for treating or preventing an HIV infection in a subject (e.g. , a human) is disclosed. In certain embodiments, a compound of any of Formula I, II, III, IV, V, and/or VI, or a pharmaceutically acceptable salt thereof, for use in the prophylactic or therapeutic treatment of an HIV infection is disclosed.

[0055] In some embodiments, the present disclosure provides a method of treating human immunodeficiency virus-1 (HIV-1) infection in a heavily treatment-experienced patient with multidrug resistant HIV-1, the method including administering to the patient a compound of the disclosure (e.g., a compound of any of Formulas I- VI), or a pharmaceutically acceptable salt thereof.

[0056] In the disclosed methods, the heavily treatment-experienced patient is infected with multidrug resistant HIV. In some embodiments, the heavily treatment-experienced patient has a multidrug resistant HIV infection and is on a failing HIV treatment regimen. In some embodiments, the heavily treatment-experienced patient has a viral load greater than about 1,000 copies of HIV RNA/mL.

[0057] In some embodiments, the HIV infection is an HIV-1 infection. In some embodiments, the HIV-1 infection is characterized by HIV-1 mutant resistance to an antiretroviral medication, for example, to one, two, three, four, or more classes of antiretroviral medications (e.g., Pls, NRTIs, NNRTIs, INSTIs, etc.). In some embodiments, the HIV-1 infection is characterized by HIV-1 mutant resistance to one or more classes of antiretroviral medications. In some embodiments, the HIV-1 infection is characterized by HIV-1 mutant resistance to two or more classes of antiretroviral medications. In some embodiments, the HIV-1 infection is characterized by HIV-1 mutant resistance to three or more classes of antiretroviral medications.

[0058] In some embodiments, the HIV-1 infection is characterized by an HIV-1 mutant that includes, but is not limited to:

(a) an HIV-1 mutant resistant to a PI (e.g., I50V, I84V/L90M, G48V/V82A/L90M, G48V/V82S, etc.);

(b) an HIV-1 mutant resistant to an NRTI (e.g., K65R, M184V, 6TAMs, etc.);

(c) an HIV-1 mutant resistant to an NNRTI (e.g., K103N, Y181C, Y188L, L100FK103N, K103N/Y181C, etc.); and/or (d) an HIV-1 mutant resistant to an INSTI (Y143R, E138K/Q148K, G140S/Q148R, E92Q/N155H, N155H/Q148R, R263K/M50I, etc.).

[0059] In some embodiments, the patient is infected with HIV-1 that is resistant to at least one antiretroviral medication. In some embodiments, the patient is infected with multidrug resistant HIV-1. In some embodiments, the patient is infected with multidrug resistant HIV-1 that is resistant to at least one, two, three, four, or more antiretroviral medications. In some embodiments, the patient is infected with multidrug resistant HIV-1 that is resistant to at least one antiretroviral medication from each of two different classes of antiretroviral medications. In some embodiments, the patient is infected with multidrug resistant HIV-1 that is resistant to at least one antiretroviral medication from each of three different classes of antiretroviral medications. In some embodiments, the different classes of antiretroviral medications are selected from a nucleoside reverse transcriptase inhibitor (NRTI), a non-nucleoside reverse transcriptase inhibitor (NNRTI), a protease inhibitor (PI), and an integrase strand transfer inhibitor (INSTI). In some embodiments, the different classes of antiretroviral medications are selected from an NRTI, an NNRTI, and a PI. In some embodiments, the patient is infected with multidrug resistant HIV-1 that is resistant to at least one NRTI and at least one NNRTI. In some embodiments, the patient is infected with multidrug resistant HIV-1 that is resistant to at least one NRTI and at least one PI. In some embodiments, the patient is infected with multidrug resistant HIV-1 that is resistant to at least one NRTI and at least one INSTI. In some embodiments, the patient is infected with multidrug resistant HIV-1 that is resistant to at least one NNRTI and at least one PI. In some embodiments, the patient is infected with multidrug resistant HIV-1 that is resistant to at least one NNRTI and at least one INSTI. In some embodiments, the patient is infected with multidrug resistant HIV-1 that is resistant to at least one PI and at least one INSTI. In some embodiments, the patient is infected with multidrug resistant HIV-1 that is resistant to at least one NRTI, at least one NNRTI, and at least one PI. In some embodiments, the patient is infected with multidrug resistant HIV-1 that is resistant to at least one NRTI, at least one NNRTI, and at least one INSTI. In some embodiments, the patient is infected with multidrug resistant HIV-1 that is resistant to at least one NRTI, at least one PI, and at least one INSTI. In some embodiments, the patient is infected with multidrug resistant HIV-1 that is resistant to at least one NNRTI, at least one PI, and at least one INSTI. In some embodiments, the patient is infected with multidrug resistant HIV-1 that is resistant to at least one NRTI, at least one NNRTI, at least one PI, and at least one INSTI. [0060] In some embodiments, the patient is infected with multidrug resistant HIV-1 that is resistant to at least one antiretroviral medication that is an NRTI. Examples of NRTIs include, but are not limited to, emtricitabine (FTC; Emtriva®), lamivudine (3TC; Epivir®), zidovudine (azidothymidine (AZT); Retrovir®), didanosine (ddl; Videx-EC®), dideoxyinosine (Videx®), tenofovir, tenofovir alafenamide (Vemlidy®), tenofovir disoproxil fumarate (Viread®), stavudine (d4T; Zerit®), zalcitabine (dideoxycytidine, ddC; Hivid®), and abacavir (Ziagen®).

[0061] In some embodiments, the patient is infected with multidrug resistant HIV-1 that is resistant to at least one antiretroviral medication that is an NNRTI. Examples of NNRTIs include, but are not limited to, efavirenz (Sustiva®), etravirine (Intelence®), rilpivirine (Edurant®), nevirapine (Viramune®), and delavirdine (Rescriptor®).

[0062] In some embodiments, the patient is infected with multidrug resistant HIV-1 that is resistant to at least one antiretroviral medication that is a PI. Examples of Pls include, but are not limited to, amprenavir (Agenerase®), atazanavir (Reyataz®), darunavir (Prezista®), fosamprenavir (Telzir®, Lexiva®), indinavir (Crixivan®), lopinavir (Kaletra®), nelfinavir (Viracept®), ritonavir (Norvir®), saquinavir (Invirase®), and tipranavir (Aptivus®).

[0063] In some embodiments, the patient is infected with multidrug resistant HIV-1 that is resistant to at least one antiretroviral medication that is an INSTI. Examples of INSTIs include, but are not limited to, raltegravir (Isentress®), elvitegravir (Vitekta®), dolutegravir (Tivicay®), cabotegravir, and bictegravir.

[0064] In some embodiments, the patient is infected with multidrug resistant HIV-1 that is resistant to at least one antiretroviral medication that is a gp41 fusion inhibitor. Examples of gp41 fusion inhibitors include, but are not limited to, albuvirtide, enfuvirtide, BMS-986197, enfuvirtide biobetter, enfuvirtide biosimilar, HIV-1 fusion inhibitors (P26-Bapc), ITV-1 , ITV-2, ITV-3, ITV-4, PIE-12 trimer and sifuvirtide.

[0065] In some embodiments, the patient is infected with multidrug resistant HIV-1 that is resistant to at least one antiretroviral medication that is a CCR5 co-receptor antagonist.

Examples of CCR5 co-receptor antagonists include, but are not limited to, aplaviroc, vicriviroc, maraviroc, cenicriviroc, PRO- 140, adaptavir (RAP-101), nifeviroc (TD-0232), anti-GP120/CD4 or CCR5 bispecific antibodies, B-07, MB-66, polypeptide C25P, TD-0680, and vMIP (Haimipu). [0066] In some embodiments the disclosed methods, the patient has been previously treated with at least one antiretroviral medication before being treated with a compound of Formula I, II, III, IV, V, and/or VI, or a pharmaceutically acceptable salt thereof. In some embodiments, the patient has been previously treated with at least one antiretroviral medication for at least 3 months, such as at least 4 months, at least 5 months, at least 6 months, at least 7 months, at least 8 months, at least 9 months, at least 10 months, at least 11 months, at least 12 months, at least 18 months, or at least 24 months. In some embodiments, the patient has been previously treated with at least one antiretroviral medication for at least 3 months. In some embodiments, the patient has been previously treated with at least one antiretroviral medication for at least 6 months. In some embodiments, the patient has been previously treated with at least one antiretroviral medication for at least 9 months. In some embodiments, the patient has been previously treated with at least one antiretroviral medication for at least 12 months. In some embodiments, the patient has been previously treated with at least one antiretroviral medication for at least 18 months. In some embodiments, the patient has been previously treated with at least one antiretroviral medication for at least 24 months. In some embodiments, the patient has been previously treated with at least one antiretroviral medication for at least 30 months. In some embodiments, the patient has been previously treated with at least one antiretroviral medication for at least 36 months.

[0067] In some embodiments, the patient has failed or is failing an HIV treatment regimen before being treated with a compound of Formula I, II, III, IV, V, and/or VI, or a pharmaceutically acceptable salt thereof. In some embodiments, the prior HIV treatment regimen included administering at least one antiretroviral medication. In some embodiments, the patient infected with HIV has relapsed after an initial response to the prior HIV treatment regimen, for example, antiretroviral therapy. In some embodiments, the patient has a viral load of greater than about 50 copies of HIV RNA/mL after about 48 weeks of therapy, for example, antiretroviral therapy, before being treated with a compound of Formula I, II, III, IV, V, and/or VI, or a pharmaceutically acceptable salt thereof.

[0068] In some embodiments, the prior treatment regimen includes administering at least one antiretroviral medication from each of two different classes of antiretroviral medications. In some embodiments, the prior treatment regimen includes administering at least one antiretroviral medication from each of three different classes of antiretroviral medications. In some embodiments, the different classes of antiretroviral medications are selected from a nucleoside reverse transcriptase inhibitor (NRTI), a non-nucleoside reverse transcriptase inhibitor (NNRTI), a protease inhibitor (PI), and an integrase strand transfer inhibitor (INSTI). In some embodiments, the different classes of antiretroviral medications are selected from an NRTI, an NNRTI, and a PI. In some embodiments, the prior treatment regimen includes administering at least one NRTI and at least one NNRTI. In some embodiments, the prior treatment regimen includes administering at least one NRTI and at least one PI. In some embodiments, the prior treatment regimen includes administering at least one NRTI and at least one INSTI. In some embodiments, the prior treatment regimen includes administering at least one NNRTI and at least one PI. In some embodiments, the prior treatment regimen includes administering at least one NNRTI and at least one INSTI. In some embodiments, the prior treatment regimen includes administering at least one PI and at least one INSTI. In some embodiments, the prior treatment regimen includes administering at least one NRTI, at least one NNRTI, and at least one PI. In some embodiments, the prior treatment regimen includes administering at least one NRTI, at least one NNRTI, and at least one INSTI. In some embodiments, the prior treatment regimen includes administering at least one NRTI, at least one PI, and at least one INSTI. In some embodiments, the prior treatment regimen includes administering at least one NNRTI, at least one PI, and at least one INSTI.

[0069] In some embodiments, the prior treatment regimen includes administering at least one antiretroviral medication that is a gp41 fusion inhibitor.

[0070] In some embodiments, the prior treatment regimen includes administering at least one antiretroviral medication that is a CCR5 co-receptor antagonist.

[0071] In some embodiments, the prior treatment regimen includes administering at least one antiretroviral medication that is an NRTI. Examples of NRTIs include, but are not limited to, emtricitabine (FTC; Emtriva®), lamivudine (3TC; Epivir®), zidovudine (azidothymidine (AZT); Retrovir®), didanosine (ddl; Videx-EC®), dideoxyinosine (Videx®), tenofovir, tenofovir alafenamide (Vemlidy®), tenofovir disoproxil fumarate (Viread®), stavudine (d4T; Zerit®), zalcitabine (dideoxycytidine, ddC; Hivid®), and abacavir (Ziagen®).

[0072] In some embodiments, the prior treatment regimen includes administering at least one antiretroviral medication that is an NNRTI. Examples of NNRTIs include, but are not limited to, efavirenz (Sustiva®), etravirine (Intelence®), rilpivirine (Edurant®), nevirapine (Viramune®), and delavirdine (Rescriptor®). [0073] In some embodiments, the prior treatment regimen includes administering at least one antiretroviral medication that is a PI. Examples of Pls include, but are not limited to, amprenavir (Agenerase®), atazanavir (Reyataz®), darunavir (Prezista®), fosamprenavir (Telzir®, Lexiva®), indinavir (Crixivan®), lopinavir (Kaletra®), nelfinavir (Viracept®), ritonavir (Norvir®), saquinavir (Invirase®), and tipranavir (Aptivus®).

[0074] In some embodiments, the prior treatment regimen includes administering at least one antiretroviral medication that is an INSTI. Examples of INSTIs include, but are not limited to, raltegravir (Isentress®), elvitegravir (Vitekta®), dolutegravir (Tivicay®), cabotegravir, and bictegravir.

[0075] In some embodiments, the prior treatment regimen includes administering at least one antiretroviral medication that is a gp41 fusion inhibitor. Examples of gp41 fusion inhibitors include, but are not limited to, albuvirtide, enfuvirtide, BMS-986197, enfuvirtide biobetter, enfuvirtide biosimilar, HIV-1 fusion inhibitors (P26-Bapc), ITV-1, ITV-2, ITV-3, ITV-4, PIE- 12 trimer and sifuvirtide.

[0076] In some embodiments, the prior treatment regimen includes administering at least one antiretroviral medication that is a CCR5 co-receptor antagonist. Examples of CCR5 coreceptor antagonists include, but are not limited to, aplaviroc, vicriviroc, maraviroc, cenicriviroc, PRO-140, adaptavir (RAP-101), nifeviroc (TD-0232), anti-GP120/CD4 or CCR5 bispecific antibodies, B-07, MB-66, polypeptide C25P, TD-0680, and vMlP (Haimipu).

[0077] In some embodiments the disclosed methods, the heavily treatment-experienced patient infected with HIV has a viral load of about 200 copies of HIV-1 RNA/mL (c/mL) to about 1,000,000 c/mL at the time of beginning administration of the compound of Formula I, II, III, IV, V, and/or VI, or a pharmaceutically acceptable salt thereof, such as a viral load of about 200 c/mL to about 500,000 c/mL, about 200 c/mL to about 250,000 c/mL, about 200 c/mL to about 100,000 c/mL, about 200 c/mL to about 50,000 c/mL, about 200 c/mL to about 25,000 c/mL, about 200 c/mL to about 10,000 c/mL, about 200 c/mL to about 5,000 c/mL, about 200 c/mL to about 3,000 c/mL, about 200 c/mL to about 2,000 c/mL, about 200 c/mL to about 1,000 c/mL, about 200 c/mL to about 750 c/mL, about 200 c/mL to about 500 c/mL, about 500 c/mL to about 1,000,000 c/mL, about 500 c/mL to about 500,000 c/mL, about 500 c/mL to about 250,000 c/mL, about 500 c/mL to about 100,000 c/mL, about 500 c/mL to about 50,000 c/mL, about 500 c/mL to about 25,000 c/mL, about 500 c/mL to about 10,000 c/mL, about 500 c/mL to about 5,000 c/mL, about 500 c/mL to about 3,000 c/mL, about 500 c/mL to about 2,000 c/mL, about 500 c/mL to about 1,000 c/mL, about 500 c/mL to about 750 c/mL, about 750 c/mL to about 1,000,000 c/mL, about 750 c/mL to about 500,000 c/mL, about 750 c/mL to about 250,000 c/mL, about 750 c/mL to about 100,000 c/mL, about 750 c/mL to about 50,000 c/mL, about 750 c/mL to about 25,000 c/mL, about 750 c/mL to about 10,000 c/mL, about 750 c/mL to about 5,000 c/mL, about 750 c/mL to about 3,000 c/mL, about 750 c/mL to about 2,000 c/mL, about 750 c/mL to about 1,000 c/mL, about 1,000 c/mL to about 1,000,000 c/mL, about 1,000 c/mL to about 500,000 c/mL, about 1,000 c/mL to about 250,000 c/mL, about 1,000 c/mL to about 100,000 c/mL, about 1,000 c/mL to about 50,000 c/mL, about 1,000 c/mL to about 25,000 c/mL, about 1,000 c/mL to about 10,000 c/mL, about 1,000 c/mL to about 5,000 c/mL, about 1,000 c/mL to about 3,000 c/mL, about 1,000 c/mL to about 2,000 c/mL, about 2,000 c/mL to about 1,000,000 c/mL, about 2,000 c/mL to about 500,000 c/mL, about 2,000 c/mL to about 250,000 c/mL, about 2,000 c/mL to about 100,000 c/mL, about 2,000 c/mL to about 50,000 c/mL, about 2,000 c/mL to about 25,000 c/mL, about 2,000 c/mL to about 10,000 c/mL, about 2,000 c/mL to about 5,000 c/mL, about 2,000 c/mL to about 3,000 c/mL, about 3,000 c/mL to about 1,000,000 c/mL, about 3,000 c/mL to about 500,000 c/mL, about 3,000 c/mL to about 250,000 c/mL, about 3,000 c/mL to about 100,000 c/mL, about 3,000 c/mL to about 50,000 c/mL, about 3,000 c/mL to about 25,000 c/mL, about 3,000 c/mL to about 10,000 c/mL, about 3,000 c/mL to about 5,000 c/mL, about 5,000 c/mL to about 1,000,000 c/mL, about 5,000 c/mL to about 500,000 c/mL, about 5,000 c/mL to about 250,000 c/mL, about 5,000 c/mL to about 100,000 c/mL, about 5,000 c/mL to about 50,000 c/mL, about 5,000 c/mL to about 25,000 c/mL, about 5,000 c/mL to about 10,000 c/mL, about 10,000 c/mL to about 1,000,000 c/mL, about 10,000 c/mL to about 500,000 c/mL, about 10,000 c/mL to about 250,000 c/mL, about 10,000 c/mL to about 100,000 c/mL, about 10,000 c/mL to about 50,000 c/mL, about 10,000 c/mL to about 25,000 c/mL, about 25,000 c/mL to about 1,000,000 c/mL, about 25,000 c/mL to about 500,000 c/mL, about 25,000 c/mL to about 250,000 c/mL, about 25,000 c/mL to about 100,000 c/mL, about 25,000 c/mL to about 50,000 c/mL, about 50,000 c/mL to about 1,000,000 c/mL, about 50,000 c/mL to about 500,000 c/mL, about 50,000 c/mL to about 250,000 c/mL, about 50,000 c/mL to about 100,000 c/mL, about 100,000 c/mL to about 1,000,000 c/mL, about 100,000 c/mL to about 500,000 c/mL, about 100,000 c/mL to about 250,000 c/mL, about 250,000 c/mL to about 1,000,000 c/mL, about 250,000 c/mL to about 500,000 c/mL, or about 500,000 c/mL to about 1,000,000 c/mL. [0078] In some embodiments, the patient has a viral load of greater than about 200 copies of HIV- 1 RNA/mL (c/mL) at the time of beginning administration of the compound of Formula I, II, III, IV, V, and/or VI, or a pharmaceutically acceptable salt thereof, such as a viral load greater than about 500 c/mL, about 750 c/mL, about 1,000 c/mL, about 2,000 c/mL, about 3,000 c/mL, about 5,000 c/mL, about 10,000 c/mL, about 25,000 c/mL, about 50,000 c/mL, about 100,000 c/mL, about 250,000 c/mL, about 500,000 c/mL, or greater than about 1,000,000 c/mL at the time of beginning administration of the compound of Formula I, II, III, IV, V, and/or VI, or a pharmaceutically acceptable salt thereof. In some embodiments, the patient has a viral load of greater than about 200 c/mL at the time of beginning administration of the compound of Formula I, II, III, IV, V, and/or VI, or a pharmaceutically acceptable salt thereof. In some embodiments, the patient has a viral load of greater than about 500 c/mL at the time of beginning administration of the compound of Formula I, II, III, IV, V, and/or VI, or a pharmaceutically acceptable salt thereof. In some embodiments, the patient has a viral load of greater than about 750 c/mL at the time of beginning administration of the compound of Formula I, II, III, IV, V, and/or VI, or a pharmaceutically acceptable salt thereof. In some embodiments, the patient has a viral load of greater than about 1,000 c/mL at the time of beginning administration of the compound of Formula I, II, III, IV, V, and/or VI, or a pharmaceutically acceptable salt thereof. In some embodiments, the patient has a viral load of greater than about 2,000 c/mL at the time of beginning administration of the compound of Formula I, II, III, IV, V, and/or VI, or a pharmaceutically acceptable salt thereof.

[0079] In certain embodiments the disclosed methods, the heavily treatment-experienced patient is concurrently being treated with at least one additional antiretroviral medication. In some embodiments, the antiretroviral medication is selected from an NRTI, an NNRTI, a PI, an INSTI, a gp41 fusion inhibitor, and a CCR5 co-receptor antagonist.

[0080] In some embodiments, the patient is concurrently being treated with at least one NRTI. Examples of NRTIs include, but are not limited to, emtricitabine (FTC; Emtriva®), lamivudine (3TC; Epivir®), zidovudine (azidothymidine (AZT); Retrovir®), didanosine (ddl; Videx-EC®), dideoxyinosine (Videx®), tenofovir, tenofovir alafenamide (Vemlidy®), tenofovir disoproxil fumarate (Viread®), stavudine (d4T; Zerit®), zalcitabine (dideoxycytidine, ddC; Hivid®), and abacavir (Ziagen®). [0081] In some embodiments, the patient is concurrently being treated with at least one NNRTI. Examples of NNRTIs include, but are not limited to, efavirenz (Sustiva®), etravirine (Intelence®), rilpivirine (Edurant®), nevirapine (Viramune®), and delavirdine (Rescriptor®).

[0082] In some embodiments, the patient is concurrently being treated with at least one PI. Examples of Pls include, but are not limited to, amprenavir (Agenerase®), atazanavir (Reyataz®), darunavir (Prezista®), fosamprenavir (Telzir®, Lexiva®), indinavir (Crixivan®), lopinavir (Kaletra®), nelfinavir (Viracept®), ritonavir (Norvir®), saquinavir (Invirase®), and tipranavir (Aptivus®).

[0083] In some embodiments, the patient is concurrently being treated with at least one INSTI. Examples of INSTIs include, but are not limited to, raltegravir (Isentress®), elvitegravir (Vitekta®), dolutegravir (Tivicay®), cabortegravir, and bictegravir.

[0084] In some embodiments, the patient is concurrently being treated with at least one gp41 fusion inhibitor. Examples of gp41 fusion inhibitors include, but are not limited to, albuvirtide, enfuvirtide, BMS-986197, enfuvirtide biobetter, enfuvirtide biosimilar, HIV-1 fusion inhibitors (P26-Bapc), ITV-1, ITV-2, ITV-3, ITV-4, PIE-12 trimer, and sifuvirtide.

[0085] In some embodiments, the patient is concurrently being treated with at least one CCR5 co-receptor antagonist. Examples of CCR5 co-receptor antagonists include, but are not limited to, aplaviroc, vicriviroc, maraviroc, cenicriviroc, PRO- 140, adaptavir (RAP- 101), nifeviroc (TD-0232), anti-GP120/CD4 or CCR5 bispecific antibodies, B-07, MB-66, polypeptide C25P, TD-0680, and vMIP (Haimipu).

[0086] Also provided in this disclosure is a method of treating an HIV-1 infection in a heavily treatment-experienced patient with multidrug resistant HIV-1 that includes administering a therapeutically effective amount of a compound of Formula I, II, III, IV, V, and/or VI, or a pharmaceutically acceptable salt thereof, to a patient that had been previously treated with an HIV treatment regimen that includes the administration of at least one antiretroviral medication and had failed the treatment regimen. In some embodiments, the HIV treatment regimen includes administration of at least one antiretroviral medication such as those described herein. In some embodiments of the method, administration of the compound or Formula I, II, III, IV, V, and/or VI, or a pharmaceutically acceptable salt thereof, results in a reduction in HIV viral load in the patient. [0087] Also disclosed is a method of treating an HIV-1 infection in a heavily treatment- experienced patient with multidrug resistant HIV-1 that includes administering a therapeutically effective amount of a compound of Formula I, II, III, IV, V, and/or VI, or a pharmaceutically acceptable salt thereof, to a patient that had been previously treated with an HIV treatment regimen that includes the administration of at least one antiretroviral medication and had failed the treatment regimen, where the multidrug resistant HIV-1 is resistant to at least one antiretroviral medication from each of two different classes of antiretroviral medications. In some embodiments, the different classes of antiretroviral medications are selected from an NRTI, an NNRTI, a PI, and an INSTI.

[0088] In some embodiments, disclosed is a method of treating an HIV-1 infection in a heavily treatment-experienced patient with multidrug resistant HIV-1 that includes administering a therapeutically effective amount of a compound of Formula I, II, III, IV, V, and/or VI, or a pharmaceutically acceptable salt thereof, to a patient that had been previously treated with an HIV treatment regimen that includes the administration of at least one antiretroviral medication, and had failed the treatment regimen, where the multidrug resistant HIV-1 is resistant to at least one antiretroviral medication from each of three different classes of antiretroviral medications. In some embodiments, the different classes of antiretroviral medications are selected from an NRTI, an NNRTI, a PI, and an INSTI.

[0089] As used herein, “treatment” or “treating” is an approach for obtaining beneficial or desired results. For purposes of the present disclosure, beneficial or desired results include, but are not limited to, alleviation of a symptom and/or diminishment of the extent of a symptom and/or preventing a worsening of a symptom associated with a disease or condition. In one embodiment, “treatment” or “treating” includes one or more of the following: a) inhibiting the disease or condition (e.g., decreasing one or more symptoms resulting from the disease or condition, and/or diminishing the extent of the disease or condition); b) slowing or arresting the development of one or more symptoms associated with the disease or condition e.g., stabilizing the disease or condition, delaying the worsening or progression of the disease or condition); and/or c) relieving the disease or condition, e.g., causing the regression of clinical symptoms, ameliorating the disease state, delaying the progression of the disease, increasing the quality of life, and/or prolonging survival. [0090] As used herein, “delaying” development of a disease or condition means to defer, hinder, slow, retard, stabilize and/or postpone development of the disease or condition. This delay can be of varying lengths of time, depending on the history of the disease and/or subject being treated. As is evident to one skilled in the art, a sufficient or significant delay can, in effect, encompass prevention, in that the subject does not develop the disease or condition. For example, a method that “delays” development of AIDS is a method that reduces the probability of disease development in a given time frame and/or reduces extent of the disease in a given time frame, when compared to not using the method. Such comparisons may be based on clinical studies, using a statistically significant number of subjects. For example, the development of AIDS can be detected using known methods, such as confirming a subject’s HIV ⁺ status and assessing the subject’s T-cell count or other indication of AIDS development, such as extreme fatigue, weight loss, persistent diarrhea, high fever, swollen lymph nodes in the neck, armpits or groin, or presence of an opportunistic condition that is known to be associated with AIDS (e.g., a condition that is generally not present in subjects with functioning immune systems but does occur in AIDS patients). Development may also refer to disease progression that may be initially undetectable and includes occurrence, recurrence and onset.

[0091] As used herein, “prevention” or “preventing” refers to a regimen that protects against the onset of the disease or disorder such that the clinical symptoms of the disease do not develop. Thus, “prevention” relates to administration of a therapy (e.g., administration of a therapeutic substance) to a subject before signs of the disease are detectable in the subject (e.g., administration of a therapeutic substance to a subject in the absence of detectable infectious agent (e.g., virus) in the subject). The subject may be an individual at risk of developing the disease or disorder, such as an individual who has one or more risk factors known to be associated with development or onset of the disease or disorder. Thus, the term “preventing HIV infection” refers to administering to a subject who does not have a detectable HIV infection an anti-HIV therapeutic substance. It is understood that the subject for anti-HIV preventative therapy may be an individual at risk of contracting the HIV virus. Further, it is understood that prevention may not result in complete protection against onset of the disease or disorder. In some instances, prevention includes reducing the risk of developing the disease or disorder. The reduction of the risk may not result in complete elimination of the risk of developing the disease or disorder. [0092] As used herein, an “at risk” individual is an individual who is at risk of developing a condition to be treated. An individual “at risk” may or may not have detectable disease or condition, and may or may not have displayed detectable disease prior to the treatment of methods described herein. “At risk” denotes that an individual has one or more so- called risk factors, which are measurable parameters that correlate with development of a disease or condition and are known in the art. An individual having one or more of these risk factors has a higher probability of developing the disease or condition than an individual without these risk factor(s). For example, individuals at risk for AIDS are those having HIV.

[0093] As used herein, the term "therapeutically effective amount" or “effective amount” refers to an amount that is effective to elicit the desired biological or medical response, including the amount of a compound that, when administered to a subject for treating a disease, is sufficient to effect such treatment for the disease or to an amount that is effective to protect against the contracting or onset of a disease. The effective amount will vary depending on the compound, the disease, and its severity and the age, weight, etc., of the subject to be treated. The effective amount can include a range of amounts. As is understood in the art, an effective amount may be in one or more doses, i.e., a single dose or multiple doses may be required to achieve the desired treatment outcome. An effective amount may be considered in the context of administering one or more therapeutic agents, and a single agent may be considered to be given in an effective amount if, in conjunction with one or more other agents, a desirable or beneficial result may be or is achieved. Suitable doses of any co-administered compounds may optionally be lowered due to the combined action (e.g., additive or synergistic effects) of the compounds.

[0094] As used herein, a “heavily treatment-experienced patient” refers to an HIV- infected patient who has limited treatment options due to a multidrug resistant HIV infection. For example, in some embodiments, the “heavily treatment-experienced patient” is a patient with HIV who has developed resistance to an antiretroviral medication from at least one class of antiretroviral medications selected from the group consisting of NRTIs, NNRTIs, Pls, and INSTIs.

[0095] In some embodiments, “multidrug resistant HIV infection” means resistance to an antiretroviral medication from at least one class of antiretroviral medications selected from the group consisting of NRTIs, NNRTIs, Pls, and INSTIs. In some embodiments, “multidrug resistant HIV infection” means resistance to at least one antiretroviral medication from two classes of antiretroviral medications selected from the group consisting of NRTIs, NNRTIs, Pls, and INSTIs. In some embodiments, “multidrug resistant HIV infection” means resistance to at least one antiretroviral medication from three classes of antiretroviral medications selected from the group consisting of NRTIs, NNRTIs, Pls, and INSTIs. In some embodiments, “multidrug resistant HIV infection” means resistance to at least one antiretroviral medication from each of the four classes of antiretroviral medications selected from the group consisting of NRTIs, NNRTIs, Pls, and INSTIs.

[0096] As used herein, the term “NRTI(s)” refers to nucleoside reverse transcriptase inhibitor(s) or nucleotide reverse transcriptase inhibitor(s).

[0097] As used herein, the term “NNRTI(s)” refers to non-nucleoside reverse transcriptase inhibitor(s) or non- nucleotide reverse transcriptase inhibitor(s).

[0098] As used herein, the term “PI(s)” refers to protease inhibitor(s).

[0099] As used herein, the term “INSTI(s)” refers to integrase strand transfer inhibitor(s).

[0100] As used herein, the term “fail” or “failed” when referring to HIV therapy or an

HIV treatment regimen means a treatment outcome which precludes the use of the same agent or class in the future in a patient with HIV. This could be due to inadequate initial viral response due to pre-existing viral resistance, viral rebound due to emergent viral resistance, or inability of a patient to continue a treatment due to intolerability or safety issues.

IV. Administration

[0101] The compounds of the present disclosure or pharmaceutically acceptable salts thereof (also referred to herein as the active ingredients) can be administered by any route appropriate to the condition to be treated. Suitable routes include oral, rectal, nasal, topical (including buccal and sublingual), transdermal, vaginal and parenteral (including subcutaneous, intramuscular, intravenous, intradermal, intrathecal and epidural), and the like. It will be appreciated that the preferred route may vary with, for example, the condition of the recipient. An advantage of certain compounds disclosed herein, or pharmaceutically acceptable salts thereof, is that they are orally bioavailable and can be dosed orally. [0102] A compound of the present disclosure, or a pharmaceutically acceptable salt thereof, may be administered to an individual in accordance with an effective dosing regimen for a desired period of time or duration, such as at least about one month, at least about 2 months, at least about 3 months, at least about 6 months, or at least about 12 months or longer. In some embodiments, the compound, or a pharmaceutically acceptable salt thereof, is administered on a daily or intermittent schedule for the duration of the individual’s life.

[0103] The specific dose level of a compound of the present disclosure, or a pharmaceutically acceptable salt thereof, for any particular subject will depend upon a variety of factors including the activity of the specific compound employed, the age, body weight, general health, sex, diet, time of administration, route of administration, and rate of excretion, drug combination and the severity of the particular disease in the subject undergoing therapy. For example, a dosage may be expressed as a number of milligrams of a compound provided herein, or a pharmaceutically acceptable salt thereof, per kilogram of the subject’s body weight (mg/kg). Dosages of between about 0.1 and 150 mg/kg may be appropriate. In some embodiments, about 0.1 and 100 mg/kg may be appropriate. In other embodiments a dosage of between 0.5 and 60 mg/kg may be appropriate. Normalizing according to the subject’s body weight is particularly useful when adjusting dosages between subjects of widely disparate size, such as occurs when using the drug in both children and adult humans or when converting an effective dosage in a non-human subject such as dog to a dosage suitable for a human subject.

[0104] The dosage may also be described as a total amount of a compound described herein, or a pharmaceutically acceptable salt thereof, administered per dose. The dosage or dosing frequency of a compound of the present disclosure, or a pharmaceutically acceptable salt thereof, may be adjusted over the course of the treatment, based on the judgment of the administering physician.

[0105] The compounds of the present disclosure, or pharmaceutically acceptable salts thereof, may be administered to an individual (e.g. , a human) in a therapeutically effective amount. In some embodiments, a compound of the disclosure, or a pharmaceutically acceptable salt thereof, is administered once daily, once weekly, once monthly, once every two months, once every three months, or once every six months. In some embodiments, a compound of the disclosure, or a pharmaceutically acceptable salt thereof, is administered once daily. In some embodiments, a compound of the disclosure, or a pharmaceutically acceptable salt thereof, is administered once weekly. In some embodiments, a compound of the disclosure, or a pharmaceutically acceptable salt thereof, is administered once monthly. In some embodiments, a compound of the disclosure, or a pharmaceutically acceptable salt thereof, is administered once every two months. In some embodiments, a compound of the disclosure, or a pharmaceutically acceptable salt thereof, is administered once every three months. In some embodiments, a compound of the disclosure, or a pharmaceutically acceptable salt thereof, is administered once every six months.

[0106] The compounds provided herein, or pharmaceutically acceptable salts thereof, can be administered by any useful route and means, such as by oral or parenteral (e.g., intravenous) administration. Therapeutically effective amounts of the compound, or a pharmaceutically acceptable salt thereof, may include from about 0.00001 mg/kg body weight per day to about 10 mg/kg body weight per day, such as from about 0.0001 mg/kg body weight per day to about 10 mg/kg body weight per day, or such as from about 0.001 mg/kg body weight per day to about 1 mg/kg body weight per day, or such as from about 0.01 mg/kg body weight per day to about 1 mg/kg body weight per day, or such as from about 0.05 mg/kg body weight per day to about 0.5 mg/kg body weight per day. In some embodiments, a therapeutically effective amount of the compounds provided herein, or pharmaceutically acceptable salts thereof, include from about 0.3 mg to about 30 mg per day, or from about 30 mg to about 300 mg per day, or from about 0.3 |lg to about 30 mg per day, or from about 30 pig to about 300 |lg per day.

[0107] A compound of the present disclosure, or a pharmaceutically acceptable salt thereof, may be combined with one or more additional therapeutic agents in any dosage amount of the compound of the present disclosure or a pharmaceutically acceptable salt thereof (e.g., from 1 mg to 1000 mg of compound). Therapeutically effective amounts may include from about 0.1 mg per dose to about 1000 mg per dose, such as from about 50 mg per dose to about 500 mg per dose, or such as from about 100 mg per dose to about 400 mg per dose, or such as from about 150 mg per dose to about 350 mg per dose, or such as from about 200 mg per dose to about 300 mg per dose, or such as from about 0.01 mg per dose to about 1000 mg per dose, or such as from about 0.01 mg per dose to about 100 mg per dose, or such as from about 0.1 mg per dose to about 100 mg per dose, or such as from about 1 mg per dose to about 100 mg per dose, or such as from about 1 mg per dose to about 10 mg per dose, or such as from about 1 mg per dose to about 1000 mg per dose. Other therapeutically effective amounts of the compounds of the disclosure, or pharmaceutically acceptable salts thereof, are about 50, 100, 125, 150, 175, 200, 225, 250, 275, or 300 mg per dose. Other therapeutically effective amounts of the compounds of the disclosure, or pharmaceutically acceptable salts thereof, are about 300, 325, 350, 375, 400, 425, 450, 475, 500, 525, 550, 575, 600, 625, 650, 675, 700, 725, 750, 775, 800, 825, 850, 875, 900, 925, 950, 975, or about 1000 mg per dose,

[0108] In some embodiments, a therapeutically effective amount of the compounds the disclosure, or pharmaceutically acceptable salts thereof, is about 1 mg to about 1000 mg. In some embodiments, a therapeutically effective amount of the compounds the disclosure, or pharmaceutically acceptable salts thereof, is about 1 mg to about 900 mg. In some embodiments, a therapeutically effective amount of the compounds the disclosure, or pharmaceutically acceptable salts thereof, is about 1 mg to about 800 mg. In some embodiments, a therapeutically effective amount of the compounds the disclosure, or pharmaceutically acceptable salts thereof, is about 1 mg to about 700 mg. In some embodiments, a therapeutically effective amount of the compounds the disclosure, or pharmaceutically acceptable salts thereof, is about 1 mg to about 600 mg. In some embodiments, a therapeutically effective amount of the compounds the disclosure, or pharmaceutically acceptable salts thereof, is about 1 mg to about 500 mg. In some embodiments, a therapeutically effective amount of the compounds the disclosure, or pharmaceutically acceptable salts thereof, is about 1 mg to about 400 mg. In some embodiments, a therapeutically effective amount of the compounds the disclosure, or pharmaceutically acceptable salts thereof, is about 1 mg to about 300 mg. In some embodiments, a therapeutically effective amount of the compounds the disclosure, or pharmaceutically acceptable salts thereof, is about 1 mg to about 200 mg. In some embodiments, a therapeutically effective amount of the compounds the disclosure, or pharmaceutically acceptable salts thereof, is about 1 mg to about 100 mg. In some embodiments, a therapeutically effective amount of the compounds the disclosure, or pharmaceutically acceptable salts thereof, is about 1 mg to about 75 mg. In some embodiments, a therapeutically effective amount of the compounds the disclosure, or pharmaceutically acceptable salts thereof, is about 1 mg to about 50 mg. In some embodiments, a therapeutically effective amount of the compounds the disclosure, or pharmaceutically acceptable salts thereof, is about 1 mg to about 25 mg. In some embodiments, a therapeutically effective amount of the compounds the disclosure, or pharmaceutically acceptable salts thereof, is about 1 mg to about 20 mg. In some embodiments, a therapeutically effective amount of the compounds the disclosure, or pharmaceutically acceptable salts thereof, is about 1 mg to about 15 mg. In some embodiments, a therapeutically effective amount of the compounds the disclosure, or pharmaceutically acceptable salts thereof, is about 1 mg to about 10 mg. In some embodiments, a therapeutically effective amount of the compounds the disclosure, or pharmaceutically acceptable salts thereof, is about 1 mg to about 5 mg.

[0109] In some embodiments, a therapeutically effective amount of the compounds the disclosure, or pharmaceutically acceptable salts thereof, is about 50 mg, about 75 mg, about 100 mg, about 125 mg, about 150 mg, about 175 mg, about 200 mg, about 225 mg, about 275 mg, about 300 mg, about 350 mg, about 400 mg, about 450 mg, about 500 mg, about 550 mg, about 600 mg, about 650 mg, about 700 mg, about 750 mg, about 800 mg, about 850 mg, about 900 mg, about 950 mg, about 1000 mg, or about 1050 mg. In some embodiments, a therapeutically effective amount of the compounds the disclosure, or pharmaceutically acceptable salts thereof, is about 5 mg. In some embodiments, a therapeutically effective amount of the compounds the disclosure, or pharmaceutically acceptable salts thereof, is about 100 mg. In some embodiments, a therapeutically effective amount of the compounds the disclosure, or pharmaceutically acceptable salts thereof, is about 150 mg. In some embodiments, a therapeutically effective amount of the compounds the disclosure, or pharmaceutically acceptable salts thereof, is about 200 mg. In some embodiments, a therapeutically effective amount of the compounds the disclosure, or pharmaceutically acceptable salts thereof, is about 250 mg. In some embodiments, a therapeutically effective amount of the compounds the disclosure, or pharmaceutically acceptable salts thereof, is about 300 mg. In some embodiments, a therapeutically effective amount of the compounds the disclosure, or pharmaceutically acceptable salts thereof, is about 350 mg. In some embodiments, a therapeutically effective amount of the compounds the disclosure, or pharmaceutically acceptable salts thereof, is about 400 mg. In some embodiments, a therapeutically effective amount of the compounds the disclosure, or pharmaceutically acceptable salts thereof, is about 450 mg. In some embodiments, a therapeutically effective amount of the compounds the disclosure, or pharmaceutically acceptable salts thereof, is about 500 mg. In some embodiments, a therapeutically effective amount of the compounds the disclosure, or pharmaceutically acceptable salts thereof, is about 550 mg. In some embodiments, a therapeutically effective amount of the compounds the disclosure, or pharmaceutically acceptable salts thereof, is about 600 mg. In some embodiments, a therapeutically effective amount of the compounds the disclosure, or pharmaceutically acceptable salts thereof, is about 650 mg. In some embodiments, a therapeutically effective amount of the compounds the disclosure, or pharmaceutically acceptable salts thereof, is about 700 mg. In some embodiments, a therapeutically effective amount of the compounds the disclosure, or pharmaceutically acceptable salts thereof, is about 750 mg. In some embodiments, a therapeutically effective amount of the compounds the disclosure, or pharmaceutically acceptable salts thereof, is about 800 mg. In some embodiments, a therapeutically effective amount of the compounds the disclosure, or pharmaceutically acceptable salts thereof, is about 850 mg. In some embodiments, a therapeutically effective amount of the compounds the disclosure, or pharmaceutically acceptable salts thereof, is about 900 mg. In some embodiments, a therapeutically effective amount of the compounds the disclosure, or pharmaceutically acceptable salts thereof, is about 950 mg. In some embodiments, a therapeutically effective amount of the compounds the disclosure, or pharmaceutically acceptable salts thereof, is about 1000 mg. In some embodiments, a therapeutically effective amount of the compounds the disclosure, or pharmaceutically acceptable salts thereof, is about 1050 mg.

[0110] When administered orally, the total weekly dosage for a human subject may be between about 1 mg and 1,000 mg/week, between about 10-500 mg/week, between about SO- SOO mg/week, between about 75-200 mg/week, or between about 100-150 mg/week. In some embodiments, the total weekly dosage for a human subject may be about 100, 200, 300, 400, 500, 600, 700, 800, 900, or 1000 mg/week administered in a single dose. In some embodiments, the total weekly dosage for a human subject of the compounds the disclosure, or pharmaceutically acceptable salts thereof, may be about 100 mg administered in a single dose. In some embodiments, the total weekly dosage for a human subject of the compounds the disclosure, or pharmaceutically acceptable salts thereof, may be about 150 mg administered in a single dose. In some embodiments, the total weekly dosage for a human subject of the compounds the disclosure, or pharmaceutically acceptable salts thereof, may be about 200 mg administered in a single dose. In some embodiments, the total weekly dosage for a human subject of the compounds the disclosure, or pharmaceutically acceptable salts thereof, may be about 250 mg administered in a single dose. In some embodiments, the total weekly dosage for a human subject of the compounds the disclosure, or pharmaceutically acceptable salts thereof, may be about 300 mg administered in a single dose. In some embodiments, the total weekly dosage for a human subject of the compounds the disclosure, or pharmaceutically acceptable salts thereof, may be about 350 mg administered in a single dose. In some embodiments, the total weekly dosage for a human subject of the compounds the disclosure, or pharmaceutically acceptable salts thereof, may be about 400 mg administered in a single dose. In some embodiments, the total weekly dosage for a human subject of the compounds the disclosure, or pharmaceutically acceptable salts thereof, may be about 450 mg administered in a single dose. In some embodiments, the total weekly dosage for a human subject of the compounds the disclosure, or pharmaceutically acceptable salts thereof, may be about 500 mg administered in a single dose.

[0111] When administered orally, the total monthly dosage for a human subject of the compounds the disclosure, or pharmaceutically acceptable salts thereof, may be between about 500 mg and 1,000 mg/month, between about 600-900 mg/month, or between about 700-800 mg/month. In some embodiments, the total weekly dosage for the compounds the disclosure, or pharmaceutically acceptable salts thereof, may be about 100, 200, 300, 400, 500, 600, 700, 800, 900, or 1000 mg/week administered in a single dose. In some embodiments, the total monthly dosage for a human subject of the compounds the disclosure, or pharmaceutically acceptable salts thereof, may be about 500 mg administered in a single dose. In some embodiments, the total monthly dosage for a human subject may be about 550 mg administered in a single dose. In some embodiments, the total monthly dosage for a human subject of the compounds the disclosure, or pharmaceutically acceptable salts thereof, may be about 600 mg administered in a single dose. In some embodiments, the total monthly dosage for a human subject of the compounds the disclosure, or pharmaceutically acceptable salts thereof, may be about 650 mg administered in a single dose. In some embodiments, the total monthly dosage of the compounds the disclosure, or pharmaceutically acceptable salts thereof, may be about 700 mg administered in a single dose. In some embodiments, the total monthly dosage for a human subject of the compounds the disclosure, or pharmaceutically acceptable salts thereof, may be about 750 mg administered in a single dose. In some embodiments, the total monthly dosage for a human subject of the compounds the disclosure, or pharmaceutically acceptable salts thereof, may be about 800 mg administered in a single dose. In some embodiments, the total monthly dosage for a human subject of the compounds the disclosure, or pharmaceutically acceptable salts thereof, may be about 850 mg administered in a single dose. In some embodiments, the total monthly dosage for a human subject of the compounds the disclosure, or pharmaceutically acceptable salts thereof, may be about 900 mg administered in a single dose. In some embodiments, the total monthly dosage for a human subject of the compounds the disclosure, or pharmaceutically acceptable salts thereof, may be about 950 mg administered in a single dose. In some embodiments, the total monthly dosage for a human subject of the compounds the disclosure, or pharmaceutically acceptable salts thereof, may be about 1000 mg administered in a single dose.

[0112] A single dose can be administered hourly, daily, weekly, or monthly. For example, a single dose can be administered once every 1 hour, 2, 3, 4, 6, 8, 12, 16 or once every 24 hours. A single dose can also be administered once every 1 day, 2, 3, 4, 5, 6, or once every 7 days. A single dose can also be administered once every 1 week, 2, 3, or once every 4 weeks. In certain embodiments, a single dose can be administered once every week. A single dose can also be administered once every month. In some embodiments, a compound provided herein, or a pharmaceutically acceptable salt thereof, is administered once daily in a method disclosed herein. In some embodiments, a compound provided herein, or a pharmaceutically acceptable salt thereof, is administered twice daily in a method disclosed herein.

[0113] In some embodiments, a compound provided herein, or a pharmaceutically acceptable salt thereof, is administered once daily in a method disclosed herein. In some embodiments, a compound provided herein, or a pharmaceutically acceptable salt thereof, is administered once weekly in a method disclosed herein. In some embodiments, a compound provided herein, or a pharmaceutically acceptable salt thereof, is administered once monthly in a method disclosed herein. In some embodiments, a compound provided herein, or a pharmaceutically acceptable salt thereof, is administered once every two months in a method disclosed herein. In some embodiments, a compound provided herein, or a pharmaceutically acceptable salt thereof, is administered once every three months in a method disclosed herein. In some embodiments, a compound provided herein, or a pharmaceutically acceptable salt thereof, is administered once every six months in a method disclosed herein.

[0114] In some embodiments, a compound provided herein, or a pharmaceutically acceptable salt thereof, is administered orally in a single dose of about 100 mg once weekly. In some embodiments, a compound provided herein, or a pharmaceutically acceptable salt thereof, is administered orally in a single dose of about 150 mg once weekly. In some embodiments, a compound provided herein, or a pharmaceutically acceptable salt thereof, is administered orally in a single dose of about 200 mg once weekly. In some embodiments, a compound provided herein, or a pharmaceutically acceptable salt thereof, is administered orally in a single dose of about 250 mg once weekly. In some embodiments, a compound provided herein, or a pharmaceutically acceptable salt thereof, is administered orally in a single dose of about 300 mg once weekly. In some embodiments, a compound provided herein, or a pharmaceutically acceptable salt thereof, is administered orally in a single dose of about 350 mg once weekly. In some embodiments, a compound provided herein, or a pharmaceutically acceptable salt thereof, is administered orally in a single dose of about 400 mg once weekly. In some embodiments, a compound provided herein, or a pharmaceutically acceptable salt thereof, is administered orally in a single dose of about 450 mg once weekly. In some embodiments, a compound provided herein, or a pharmaceutically acceptable salt thereof, is administered orally in a single dose of about 500 mg once weekly.

[0115] In some embodiments, a compound provided herein, or a pharmaceutically acceptable salt thereof, is administered orally in a single dose of about 500 mg once monthly. In some embodiments, a compound provided herein, or a pharmaceutically acceptable salt thereof, is administered orally in a single dose of about 550 mg once monthly. In some embodiments, a compound provided herein, or a pharmaceutically acceptable salt thereof, is administered orally in a single dose of about 600 mg once monthly. In some embodiments, a compound provided herein, or a pharmaceutically acceptable salt thereof, is administered orally in a single dose of about 650 mg once monthly. In some embodiments, a compound provided herein, or a pharmaceutically acceptable salt thereof, is administered orally in a single dose of about 700 mg once monthly. In some embodiments, a compound provided herein, or a pharmaceutically acceptable salt thereof, is administered orally in a single dose of about 750 mg once monthly. In some embodiments, a compound provided herein, or a pharmaceutically acceptable salt thereof, is administered orally in a single dose of about 800 mg once monthly. In some embodiments, a compound provided herein, or a pharmaceutically acceptable salt thereof, is administered orally in a single dose of about 850 mg once monthly. In some embodiments, a compound provided herein, or a pharmaceutically acceptable salt thereof, is administered orally in a single dose of about 900 mg once monthly. In some embodiments, a compound provided herein, or a pharmaceutically acceptable salt thereof, is administered orally in a single dose of about 950 mg once monthly. In some embodiments, a compound provided herein, or a pharmaceutically acceptable salt thereof, is administered orally in a single dose of about 1000 mg once monthly.

[0116] The frequency of dosage of the compound of the present disclosure, or a pharmaceutically acceptable salt thereof, will be determined by the needs of the individual patient and can be, for example, once per day, once per week, once per month, once per every two months, once per every three months, or once per every six months. Administration of the compound, or a pharmaceutically acceptable salt thereof, continues for as long as necessary to treat the Retroviridae infection, including an HIV infection, or any other indication described herein. For example, a compound, or a pharmaceutically acceptable salt thereof, can be administered to a human suffering from a Retroviridae infection, including an HIV infection, for the duration of the human’s life.

[0117] Administration can be intermittent, with a period of several or more days during which a patient receives a daily dose of the compound of the present disclosure, or a pharmaceutically acceptable salt thereof, followed by a period of several or more days during which a patient does not receive a daily dose of the compound or a pharmaceutically acceptable salt thereof. For example, a patient can receive a dose of the compound, or a pharmaceutically acceptable salt thereof, every other day, or three times per week. Again by way of example, a patient can receive a dose of the compound, or a pharmaceutically acceptable salt thereof, each day for a period of from 1 to 14 days, followed by a period of 7 to 21 days during which the patient does not receive a dose of the compound, or a pharmaceutically acceptable salt thereof, followed by a subsequent period (e.g., from 1 to 14 days) during which the patient again receives a daily dose of the compound, or a pharmaceutically acceptable salt thereof.

Alternating periods of administration of the compound, or a pharmaceutically acceptable salt thereof, followed by non- administration of the compound, or a pharmaceutically acceptable salt thereof, can be repeated as clinically required to treat the patient.

[0118] The compounds of the present disclosure, or pharmaceutically acceptable salts thereof, or the pharmaceutical compositions of the present disclosure may be administered once, twice, three, or four times daily, using any suitable mode described above. Also, administration or treatment with the compounds, or pharmaceutically acceptable salts thereof, may be continued for a number of days; for example, commonly treatment would continue for at least 7 days, 14 days, or 28 days, for one cycle of treatment. Treatment cycles are well known for Retroviridae infections, including an HIV infection. In some embodiments, treatment cycles are frequently alternated with resting periods of about 1 to 28 days, commonly about 7 days or about 14 days, between cycles. The treatment cycles, in other embodiments, may also be continuous.

V. Combination Therapy

[0119] Patients being treated by administration of the compounds provided herein, or pharmaceutically acceptable salts thereof, often exhibit diseases or conditions that benefit from treatment with other therapeutic agents, including agents that are therapeutic for Retroviridae infections, including an HIV infection. In some embodiments, the other therapeutic agent is an agent that is therapeutic for an HIV infection. Thus, one aspect of the disclosure is a method of treating an HIV infection comprising administering a compound of the present disclosure, or a pharmaceutically acceptable salt thereof, in combination with one or more compounds useful for the treatment of an HIV infection to a subject, particularly a human subject, in need thereof.

[0120] In some embodiments, a compound of the present disclosure, or a pharmaceutically acceptable salt thereof, is combined with one, two, three, four or more additional therapeutic agents. In some embodiments, a compound of the present disclosure, or a pharmaceutically acceptable salt thereof, is combined with two additional therapeutic agents. In some embodiments, a compound of the present disclosure, or a pharmaceutically acceptable salt thereof, is combined with three additional therapeutic agents. In some embodiments, a compound of the present disclosure, or a pharmaceutically acceptable salt thereof, is combined with four additional therapeutic agents. The one, two, three, four or more additional therapeutic agents can be different therapeutic agents selected from the same class of therapeutic agents, and/or they can be selected from different classes of therapeutic agents.

[0121] In some embodiments, when a compound of the present disclosure, or a pharmaceutically acceptable salt thereof, is combined with one or more additional therapeutic agents as described herein, the components of the composition are administered as a simultaneous or sequential regimen. When administered sequentially, the combination may be administered in two or more administrations.

[0122] In some embodiments, a compound of the present disclosure, or a pharmaceutically acceptable salt thereof, is combined with one or more additional therapeutic agents in a unitary dosage form for simultaneous administration to a patient, for example as a solid dosage form for oral administration.

[0123] In some embodiments, a compound of the present disclosure, or a pharmaceutically acceptable salt thereof, is co-administered with one or more additional therapeutic agents.

[0124] Co-administration includes administration of unit dosages of the compounds provided herein, or pharmaceutically acceptable salts thereof, before or after administration of unit dosages of one or more additional therapeutic agents. The compounds provided herein, or pharmaceutically acceptable salts thereof, may be administered within seconds, minutes, or hours of the administration of one or more additional therapeutic agents. For example, in some embodiments, a unit dose of a compound provided herein, or a pharmaceutically acceptable salt thereof, is administered first, followed within seconds or minutes by administration of a unit dose of one or more additional therapeutic agents. Alternatively, in other embodiments, a unit dose of one or more additional therapeutic agents is administered first, followed by administration of a unit dose of a compound provided herein, or a pharmaceutically acceptable salt thereof, within seconds or minutes. In some embodiments, a unit dose of a compound provided herein, or a pharmaceutically acceptable salt thereof, is administered first, followed, after a period of hours (i.e., 1-12 hours), by administration of a unit dose of one or more additional therapeutic agents. In other embodiments, a unit dose of one or more additional therapeutic agents is administered first, followed, after a period of hours (i.e. , 1-12 hours), by administration of a unit dose of a compound provided herein or a pharmaceutically acceptable salt thereof.

[0125] In some embodiments, one or more compounds the disclosure, or pharmaceutically acceptable salts thereof, are formulated as a tablet, which may optionally contain one or more other compounds useful for treating the disease being treated. In certain embodiments, the tablet can contain another active ingredient for treating a Retroviridae infection, including an HIV infection. In some embodiments, such tablets are suitable for once daily dosing. In some embodiments, such tablets are suitable for once weekly dosing. In some embodiments, such tablets are suitable for once monthly dosing. In some embodiments, such tablets are suitable for once every two months dosing. In some embodiments, such tablets are suitable for once every three months dosing. In some embodiments, such tablets are suitable for once every six months dosing.

[0126] Also provided herein are methods of treatment in which a compound of the disclosure, or a tautomer or pharmaceutically acceptable salt thereof, is given to a patient in combination with one or more additional therapeutic agents or therapy. In some embodiments, the total daily dosage of a compound of the disclosure, or a tautomer, or a pharmaceutically acceptable salt thereof, may be about 1 to about 500 mg administered in a single dose for a human subject. HIV Combination Therapy

[0127] In the above embodiments, the additional therapeutic agent or agents may be an anti-HIV agent. In some instances, the additional therapeutic agent can be HIV protease inhibitors, HIV non-nucleoside or non-nucleotide inhibitors of reverse transcriptase, HIV nucleoside or nucleotide inhibitors of reverse transcriptase, HIV integrase inhibitors, HIV non- catalytic site (or allosteric) integrase inhibitors, HIV entry inhibitors, HIV maturation inhibitors, HIV capsid inhibitors, nucleocapsid protein 7 (NCp7) inhibitors, HIV Tat or Rev inhibitors, inhibitors of Tat-TAR-P-TEFb, immunomodulators, immunotherapeutic agents, antibody-drug conjugates, gene modifiers, gene editors (such as CRISPR/Cas9, zinc finger nucleases, homing nucleases, synthetic nucleases, TALENs), cell therapies (such as chimeric antigen receptor T- cell, CAR-T, and engineered T-cell receptors, TCR-T, autologous T-cell therapies, engineered B cells, NK cells), latency reversing agents, immune-based therapies, phosphatidylinositol 3- kinase (PI3K) inhibitors, HIV antibodies, bispecific antibodies and “antibody-like” therapeutic proteins, HIV pl7 matrix protein inhibitors, IL- 13 antagonists, peptidyl-prolyl cis-trans isomerase A modulators, protein disulfide isomerase inhibitors, complement C5a receptor antagonists, DNA methyltransferase inhibitor, Fatty acid synthase inhibitor, HIV vif gene modulators, Vif dimerization antagonists, HIV-1 viral infectivity factor inhibitors, HIV-1 Nef modulators, TNF alpha ligand inhibitors, HIV Nef inhibitors, Hck tyrosine kinase modulators, mixed lineage kinase-3 (MLK-3) inhibitors, HIV-1 splicing inhibitors, integrin antagonists, nucleoprotein inhibitors, splicing factor modulators, COMM domain containing protein 1 modulators, HIV ribonuclease H inhibitors, IFN antagonists, retrocyclin modulators, CD3 antagonists, CDK-4 inhibitors, CDK-6 inhibitors, CDK-9 inhibitors, Cytochrome P450 3 inhibitors, CXCR4 modulators, dendritic ICAM-3 grabbing nonintegrin 1 inhibitors, HIV GAG protein inhibitors, HIV POL protein inhibitors, Complement Factor H modulators, ubiquitin ligase inhibitors, deoxycytidine kinase inhibitors, cyclin dependent kinase inhibitors, HPK1 (MAP4K1) inhibitors, proprotein convertase PC9 stimulators, ATP dependent RNA helicase DDX3X inhibitors, reverse transcriptase priming complex inhibitors, G6PD and NADH-oxidase inhibitors, mTOR complex 1 inhibitors, mTOR complex 2 inhibitors, P-Glycoprotein modulators, RNA polymerase modulators, TAT protein inhibitors, Prolyl endopeptidase inhibitors, Phospholipase A2 inhibitors, pharmacokinetic enhancers, HIV gene therapy, HIV vaccines, anti-HIV peptides, and combinations thereof.

[0128] In some embodiments, the additional therapeutic agent or agents are selected from combination drugs for HIV, other drugs for treating HIV, HIV protease inhibitors, HIV reverse transcriptase inhibitors, HIV integrase inhibitors, HIV non-catalytic site (or allosteric) integrase inhibitors, HIV entry (fusion) inhibitors, HIV maturation inhibitors, latency reversing agents, capsid inhibitors, immune-based therapies, PI3K inhibitors, HIV antibodies, and bispecific antibodies, and “antibody-like” therapeutic proteins, and combinations thereof.

[0129] In some embodiments, the additional therapeutic agent is selected from the group consisting of combination drugs for HIV, other drugs for treating HIV, HIV protease inhibitors, HIV reverse transcriptase inhibitors, HIV integrase inhibitors, HIV non-catalytic site (or allosteric) integrase inhibitors, HIV entry (fusion) inhibitors, HIV maturation inhibitors, latency reversing agents, capsid inhibitors, immune-based therapies, PI3K inhibitors, HIV antibodies, and bispecific antibodies, and “antibody-like” therapeutic proteins, and combinations thereof.

[0130] In some embodiments, the additional therapeutic agent or agents are chosen from HIV protease inhibitors, HIV non-nucleoside or non-nucleotide inhibitors of reverse transcriptase, HIV nucleoside or nucleotide inhibitors of reverse transcriptase, HIV integrase inhibitors, HIV capsid inhibitors, gp41 inhibitors, CXCR4 inhibitors, gpl20 inhibitors, CCR5 inhibitors, Nef inhibitors, latency reversing agents, HIV bNAbs, agonists of TLR7, TLR8, and TLR9, HIV vaccines, cytokines, immune checkpoint inhibitors, FLT3 ligands, T cell and NK cell recruiting bispecific antibodies, chimeric T cell receptors targeting HIV antigens, pharmacokinetic enhancers, and other drugs for treating HIV, and combinations thereof.

[0131] In some embodiments, the additional therapeutic agent or agents any are chosen from dolutegravir, cabotegravir, darunavir, bictegravir, elsulfavirine, rilpivirine, and lenacapavir, and combinations thereof.

/7/V Combination Drugs

[0132] Examples of combination drugs include, but are not limited to, ATRIPLA® (efavirenz, tenofovir disoproxil fumarate, and emtricitabine); COMPLERA® (EVIPLERA®; rilpivirine, tenofovir disoproxil fumarate, and emtricitabine); STRIBILD® (elvitegravir, cobicistat, tenofovir disoproxil fumarate, and emtricitabine); TRUVADA® (tenofovir disoproxil fumarate and emtricitabine; TDF+FTC); DESCOVY® (tenofovir alafenamide and emtricitabine); ODEFSEY® (tenofovir alafenamide, emtricitabine, and rilpivirine); GENVOYA® (tenofovir alafenamide, emtricitabine, cobicistat, and elvitegravir); darunavir, tenofovir alafenamide hemifumarate, emtricitabine, and cobicistat; efavirenz, lamivudine, and tenofovir disoproxil fumarate; lamivudine and tenofovir disoproxil fumarate; tenofovir and lamivudine; tenofovir alafenamide and emtricitabine ;tenofovir alafenamide hemifumarate and emtricitabine; tenofovir alafenamide hemifumarate, emtricitabine, and rilpivirine; tenofovir alafenamide hemifumarate, emtricitabine, cobicistat, and elvitegravir; tenofovir analog; COMBIVIR® (zidovudine and lamivudine; AZT+3TC); EPZICOM® (LIVEXA®; abacavir sulfate and lamivudine; ABC+3TC); KALETRA® (ALUVIA®; lopinavir and ritonavir); TRIUMEQ® (dolutegravir, abacavir, and lamivudine); BIKT AR VY® (bictegravir + emtricitabine + tenofovir alafenamide), DOVATO® (dolutegravir + lamivudine), TRIZIVIR® (abacavir sulfate, zidovudine, and lamivudine; ABC+AZT+3TC); atazanavir and cobicistat; atazanavir sulfate and cobicistat; atazanavir sulfate and ritonavir; darunavir and cobicistat; dolutegravir and rilpivirine; dolutegravir and rilpivirine hydrochloride; dolutegravir, abacavir sulfate, and lamivudine; lamivudine, nevirapine, and zidovudine; raltegravir and lamivudine; doravirine, lamivudine, and tenofovir disoproxil fumarate; doravirine, lamivudine, and tenofovir disoproxil; dolutegravir + lamivudine, lamivudine + abacavir + zidovudine, lamivudine + abacavir, lamivudine + tenofovir disoproxil fumarate, lamivudine + zidovudine + nevirapine, lopinavir + ritonavir, lopinavir + ritonavir + abacavir + lamivudine, lopinavir + ritonavir + zidovudine + lamivudine, tenofovir + lamivudine, and tenofovir disoproxil fumarate + emtricitabine + rilpivirine hydrochloride, lopinavir , ritonavir, zidovudine, lopinavir + ritonavir + abacavir + lamivudine, lamivudine, cabotegravir + rilpivirine, 3-BNC117 + albuvirtide, elpida (elsulfavirine, VM-1500), and VM-1500A, and dual-target HIV-1 reverse transcriptase/nucleocapsid protein 7 inhibitors.

Other HIV Drugs

[0133] Examples of other drugs for treating HIV include, but are not limited to, aspemigrin C, acemannan, alisporivir, BanLec, deferiprone, Gamimune, metenkefalin, naltrexone, Prolastin, REP 9, RPI-MN, VSSP, Hlviral, SB-728-T, 1,5-dicaffeoylquinic acid, rHIV7-shl-TAR-CCR5RZ, AAV-eCD4-Ig gene therapy, MazF gene therapy, BlockAide, bevirimat derivatives, ABBV-382, ABX-464, AG-1105, APH-0812, APH0202, bryostatin-1, bryostatin analogs, BIT-225, BRII-732, BRII-778, CYT-107, CS-TATI-1, fluoro-beta-D- arabinose nucleic acid (FANA)-modified antisense oligonucleotides, FX-101, griffithsin, GSK- 3739937, GSK-3739937 (long-acting), HGTV-43, HPH-116, HS-10234, hydroxychloroquine, IMB-10035, IMO-3100, IND-02, JL-18008, LADAVRU, MK-1376, MK-2048, MK-4250, MK- 8507, MK-8558, NOV-205, OB-002H, ODE-Bn-TFV, PA-1050040 (PA-040), PC-707, PGN- 007, QF-036, S-648414, SCY-635, SB-9200, SCB-719, TR-452, TEV-90110, TEV-90112, TEV-90111, TEV-90113, RN-18, DIACC-1010, Fasnall, Immuglo, 2-CLIPS peptide, HRF- 4467, thrombospondin analogs, TBL-1004HI, VG-1177, xl-081, AVI-CO-004, rfhSP-D, [18F]- MC-225, URMC-099-C, RES-529, Verdinexor, IMC-M113V, IML-106, antiviral fc conjugate (A VC), WP-1096, WP-1097, Gammora, ISR-CO48, ISR-48, ISR-49, MK-8527, cannabinoids, ENOB-HV-32, HiviCide-I, T-1144, VIR-576, nipamovir, Covimro, and ABBV-1882.

HIV Protease Inhibitors

[0134] Examples of HIV protease inhibitors include, but are not limited to, amprenavir, atazanavir, brecanavir, darunavir, fos amprenavir, fosamprenavir calcium, indinavir, indinavir sulfate, lopinavir, nelfinavir, nelfinavir mesylate, ritonavir, saquinavir, saquinavir mesylate, tipranavir, ASC-09 + ritonavir, AEBL-2, DG-17, GS-1156, TMB-657 (PPL-100), T-169, BL- 008, MK-8122, TMB-607, GRL-02031, and TMC-310911. Additional examples of HIV protease inhibitors are described, e.g., in U.S. Patent No. 10,294,234, and U.S. Patent Application Publication Nos. US2020030327 and US2019210978.

HIV Gag Protein Inhibitors

[0135] Examples of HIV Gag protein inhibitors include, but are not limited to, HRF- 10071.

HIV Ribonuclease H Inhibitors

[0136] Examples of HIV ribonuclease H inhibitors include, but are not limited to, NSC- 727447.

HIV Nef Inhibitors

[0137] Examples of HIV Nef inhibitors include, but are not limited to, FP-1.

HIV Reverse Transcriptase Inhibitors

[0138] Examples of HIV non-nucleoside or non-nucleotide inhibitors of reverse transcriptase include, but are not limited to, dapivirine, delavirdine, delavirdine mesylate, doravirine, efavirenz, etravirine, lentinan, nevirapine, rilpivirine, ACC-007, ACC-008, AIC-292, F-18, KM-023, PC-1005, Ml-TFV, M2-TFV, VM-1500A-LAI, PF-3450074, elsulfavirine (sustained release oral, HIV infection), elsulfavirine (long acting injectable nanosuspension, HIV infection), and elsulfavirine (VM-1500). Additional non- limiting examples of nonnucleoside or non-nucleotide inhibitors of reverse transcriptase include the compounds disclosed in U.S. Patent No. 10,548,898.

[0139] Examples of HIV nucleoside or nucleotide inhibitors of reverse transcriptase include, but are not limited to, adefovir, adefovir dipivoxil, azvudine, emtricitabine, tenofovir, tenofovir alafenamide, tenofovir alafenamide fumarate, tenofovir alafenamide hemifumarate, tenofovir disoproxil, tenofovir disoproxil fumarate, tenofovir octadecyloxyethyl ester (AGX- 1009), tenofovir disoproxil hemifumarate, VIDEX® and VIDEX EC® (didanosine, ddl), abacavir, abacavir sulfate, alovudine, apricitabine, censavudine, didanosine, elvucitabine, festinavir, fosalvudine tidoxil, CMX-157, dapivirine, doravirine, etravirine, OCR-5753, tenofovir disoproxil orotate, fozivudine tidoxil, lamivudine, phosphazid, stavudine, zalcitabine, zidovudine, rovafovir etalafenamide (GS-9131), GS-9148, MK-8504, MK-8583, VM-2500, and KP-1461.

[0140] Additional examples of HIV nucleoside or nucleotide inhibitors of reverse transcriptase include, but are not limited to, those described in patent publications US2007049754, US2016250215, US2016237062, US2016251347, US2002119443, US2013065856, US2013090473, US2014221356, and WO04096286.

HIV Integrase Inhibitors

[0141] Examples of HIV integrase inhibitors include, but are not limited to, elvitegravir, elvitegravir (extended-release microcapsules), curcumin, derivatives of curcumin, chicoric acid, derivatives of chicoric acid, 3,5-dicaffeoylquinic acid, derivatives of 3,5-dicaffeoylquinic acid, aurintricarboxylic acid, derivatives of aurintricarboxylic acid, caffeic acid phenethyl ester, derivatives of caffeic acid phenethyl ester, tyrphostin, derivatives of tyrphostin, quercetin, derivatives of quercetin, raltegravir, PEGylated raltegravir, dolutegravir, ITK-351, bictegravir, AVX-15567, cabotegravir (long acting injectable), diketo quinolin-4-1 derivatives, integrase- LEDGF inhibitor, ledgins, M-522, M-532, MK-0536, NSC-310217, NSC-371056, NSC-48240, NSC-642710, NSC-699171, NSC-699172, NSC-699173, NSC-699174, stilbenedisulfonic acid, T169, STP-0404, VM-3500, XVIR-110, and ACC-017. Additional non-limiting examples of HIV integrase inhibitors include the compounds disclosed in U.S. Patent No. 11,084,832. [0142] Examples of HIV non-catalytic site, or allosteric, integrase inhibitors (NCINI) include, but are not limited to, CX-05045, CX-05168, and CX-14442.

HIV Viral Infectivity Factor Inhibitors

[0143] Examples of HIV viral infectivity factor inhibitors include, but are not limited to, 2-amino-N-(2-methoxyphenyl)-6-((4-nitrophenyl)thio)benzamide derivatives, and Irino-L.

HIV Entry Inhibitors

[0144] Examples of HIV entry (fusion) inhibitors include, but are not limited to, AAR- 501, LBT-5001, cenicriviroc, CCR5 inhibitors, gp41 inhibitors, CD4 attachment inhibitors, gpl20 inhibitors, gpl60 inhibitors, and CXCR4 inhibitors.

[0145] Examples of CCR5 inhibitors include, but are not limited to, aplaviroc, vicriviroc, maraviroc, maraviroc (long acting injectable nanoemulsion), cenicriviroc, leronlimab (PRO- 140), adaptavir (RAP- 101), nifeviroc (TD-0232), anti-GP120/CD4 or CCR5 bispecific antibodies, B-07, MB-66, polypeptide C25P, TD-0680, thioraviroc and vMIP (Haimipu).

[0146] Examples of gp41 inhibitors include, but are not limited to, albuvirtide, enfuvirtide, griffithsin (gp41/gpl20/gpl60 inhibitor), BMS-986197, enfuvirtide biobetter, enfuvirtide biosimilar, HIV-1 fusion inhibitors (P26-Bapc), ITV-1 , ITV-2, ITV-3, ITV-4, CPT- 31, C13hmAb, lipuvirtide, PIE- 12 trimer and sifuvirtide.

[0147] Examples of CD4 attachment inhibitors include, but are not limited to, ibalizumab and CADA analogs

[0148] Examples of gpl20 inhibitors include, but are not limited to, anti-HIV microbicide, Radha-108 (receptol) 3B3-PE38, BMS818251, BanLec, bentonite-based nanomedicine, fostemsavir tromethamine, IQP-0831, VVX-004, and BMS-663068.

[0149] Examples of gpl60 inhibitors include, but are not limited to, fangchinoline.

[0150] Examples of CXCR4 inhibitors include, but are not limited to, plerixafor, ALT- 1188, N15 peptide, and vMIP (Haimipu). HIV Maturation Inhibitors

[0151] Examples of HIV maturation inhibitors include, but are not limited to, BMS- 955176, GSK-3640254 and GSK-2838232.

Latency Reversing Agents

[0152] Examples of latency reversing agents include, but are not limited to, toll-like receptor (TER) agonists (including TLR7 agonists, e.g., GS-9620, TLR8 agonists, and TLR9 agonists), histone deacetylase (HDAC) inhibitors, proteasome inhibitors such as velcade, protein kinase C (PKC) activators, Smyd2 inhibitors, BET-bromodomain 4 (BRD4) inhibitors (such as ZL-O58O, apabetalone), ionomycin, IAP antagonists (inhibitor of apoptosis proteins, such as APG-1387, LBW-242), SMAC mimetics (including TL32711, LCL161, GDC-0917, HGS1029, AT-406, Debio-1143), PMA, SAHA (suberanilohydroxamic acid, or suberoyl, anilide, and hydroxamic acid), NIZ-985, IL-15 modulating antibodies (including IL-15, IL-15 fusion proteins, and IL- 15 receptor agonists), JQ1, disulfiram, amphotericin B, and ubiquitin inhibitors such as largazole analogs, APH-0812, and GSK-343. Examples of PKC activators include, but are not limited to, indolactam, prostratin, ingenol B, and DAG-lactones.

[0153] Additional examples of TLR7 agonists include, but are not limited to, those described in U.S. Patent Application Publication No. US2010143301.

[0154] Additional examples of TLR8 agonists include, but are not limited to, those described in U.S. Patent Application Publication No. US2017071944.

Histone Deacetylase (HDAC) Inhibitors

[0155] In some embodiments, the agents as described herein are combined with an inhibitor of a histone deacetylase, e.g., histone deacetylase 1, histone deacetylase 9 (HDAC9, HD7, HD7b, HD9, HDAC, HDAC7, HDAC7B, HDAC9B, HDAC9FL, HDRP, MITR; Gene ID: 9734). Examples of HDAC inhibitors include without limitation, abexinostat, ACY-241, AR-42, BEBT-908, belinostat, CKD-581, CS-055 (HBI-8000), CT-101, CUDC-907 (fimepinostat), entinostat, givinostat, mocetinostat, panobinostat, pracinostat, quisinostat (JNJ- 26481585), resminostat, ricolinostat, romidepsin, SHP-141, TMB-ADC, valproic acid (VAL- 001), vorinostat, tinostamustine, remetinostat, and entinostat. Capsid Inhibitors

[0156] Examples of capsid inhibitors include, but are not limited to, capsid polymerization inhibitors or capsid disrupting compounds, HIV nucleocapsid p7 (NCp7) inhibitors such as azodicarbonamide, HIV p24 capsid protein inhibitors, lenacapavir (GS-6207), GS-CA1, AVI-621, AVI-101, AVI-201, AVI-301, and AVI-CAN1-15 series, PF-3450074, HIV- 1 capsid inhibitors (HIV-1 infection, Shandong University), and compounds described in (GSK W02019/087016).

[0157] Additional examples of capsid inhibitors include, but not limited to, those described in U.S. Patent Application Publication Nos. US2018051005 and US2016108030.

[0158] Additional examples of HIV capsid inhibitors include, but are not limited to, those described in U.S. Patent Application Publication Nos. US2014221356 and US2016016973.

Cytochrome P450 3 inhibitors

[0159] Examples of Cytochrome P450 3 inhibitors include, but are not limited to, those described in U.S. Patent No. 7,939,553.

RNA polymerase modulators

[0160] Examples of RNA polymerase modulators include, but are not limited to, those described in U.S. Patent Nos. 10,065,958 and 8,008,264.

Immune Checkpoint Modulators

[0161] In various embodiments, the agents as described herein, are combined with one or more blockers or inhibitors of inhibitory immune checkpoint proteins or receptors and/or with one or more stimulators, activators or agonists of one or more stimulatory immune checkpoint proteins or receptors. Blockade or inhibition of inhibitory immune checkpoints can positively regulate T-cell or NK cell activation and prevent immune escape of infected cells. Activation or stimulation of stimulatory immune check points can augment the effect of immune checkpoint inhibitors in infective therapeutics. In various embodiments, the immune checkpoint proteins or receptors regulate T cell responses (e.g., reviewed in Xu et al., 7 Exp Clin Cancer Res. (2018) 37: 110). In various embodiments, the immune checkpoint proteins or receptors regulate NK cell responses (e.g., reviewed in Davis et al., Semin Immunol. (2017) 31:64-75 and Chiossone et al., Nat Rev Immunol. (2018) 18(11):671-688).

[0162] Examples of immune checkpoint proteins or receptors include without limitation CD27, CD70; CD40, CD40LG; CD47, CD48 (SLAMF2), transmembrane and immunoglobulin domain containing 2 (TMIGD2, CD28H), CD84 (LY9B, SLAMF5), CD96, CD160, MS4A1 (CD20), CD244 (SLAMF4); CD276 (B7H3); V-set domain containing T cell activation inhibitor 1 (VTCN1, B7H4); V-set immunoregulatory receptor (VSIR, B7H5, VISTA); immunoglobulin superfamily member 11 (IGSF11, VSIG3); natural killer cell cytotoxicity receptor 3 ligand 1 (NCR3LG1, B7H6); HERV-H LTR- associating 2 (HHLA2, B7H7); inducible T cell costimulator (ICOS, CD278); inducible T cell costimulator ligand (ICOSLG, B7H2); TNF receptor superfamily member 4 (TNFRSF4, 0X40); TNF superfamily member 4 (TNFSF4, OX40L); TNFRSF8 (CD30), TNFSF8 (CD30L); TNFRSF10A (CD261, DR4, TRAILR1), TNFRSF9 (CD137), TNFSF9 (CD137L); TNFRSF10B (CD262, DR5, TRAILR2), TNFRSF10 (TRAIL); TNFRSF14 (HVEM, CD270), TNFSF14 (HVEML); CD272 (B and T lymphocyte associated (BTLA)); TNFRSF17 (BCMA, CD269), TNFSF13B (BAFF); TNFRSF18 (GITR), TNFSF18 (GITRL); MHC class I polypeptide-related sequence A (MICA); MHC class I polypeptide- related sequence B (MICB); CD274 (CD274, PDL1, PD-L1); programmed cell death 1 (PDCD1, PD1, PD-1); cytotoxic T-lymphocyte associated protein 4 (CTLA4, CD152); CD80 (B7-1), CD28; nectin cell adhesion molecule 2 (NECTIN2, CD112); CD226 (DNAM-1);

Poliovirus receptor (PVR) cell adhesion molecule (PVR, CD 155); PVR related immunoglobulin domain containing (PVRIG, CD112R); T cell immunoreceptor with Ig and ITIM domains (TIGIT); T cell immunoglobulin and mucin domain containing 4 (TIMD4; TIM4); hepatitis A virus cellular receptor 2 (HAVCR2, TIMD3, TIM3); galectin 9 (LGALS9); lymphocyte activating 3 (LAG3, CD223); signaling lymphocytic activation molecule family member 1 (SLAMF1, SLAM, CD 150); lymphocyte antigen 9 (LY9, CD229, SLAMF3); SLAM family member 6 (SLAMF6, CD352); SLAM family member 7 (SLAMF7, CD319); UL16 binding protein 1 (ULBP1); UL16 binding protein 2 (ULBP2); UL16 binding protein 3 (ULBP3); retinoic acid early transcript IE (RAET1E; ULBP4); retinoic acid early transcript IG (RAET1G; ULBP5); retinoic acid early transcript IL (RAET1L; ULBP6); lymphocyte activating 3 (CD223); killer cell immunoglobulin like receptor, three Ig domains and long cytoplasmic tail 1 (KIR, CD158E1); killer cell lectin like receptor Cl (KLRC1, NKG2A, CD159A); killer cell lectin like receptor KI (KLRK1, NKG2D, CD314); killer cell lectin like receptor C2 (KLRC2, CD 159c, NKG2C); killer cell lectin like receptor C3 (KLRC3, NKG2E); killer cell lectin like receptor C4 (KLRC4, NKG2F); killer cell immunoglobulin like receptor, two Ig domains and long cytoplasmic tail 1 (KIR2DL1); killer cell immunoglobulin like receptor, two Ig domains and long cytoplasmic tail 2 (KIR2DL2); killer cell immunoglobulin like receptor, two Ig domains and long cytoplasmic tail 3 (KIR2DL3); killer cell immunoglobulin like receptor, three Ig domains and long cytoplasmic tail 1 (KIR3DL1); killer cell lectin like receptor DI (KLRD1); SLAM family member 7 (SLAMF7); and Hematopoietic Progenitor Kinase 1 (HPK1, MAP4K1).

[0163] In various embodiments, the agents described herein are combined with one or more blockers or inhibitors of one or more T-cell inhibitory immune checkpoint proteins or receptors. Illustrative T-cell inhibitory immune checkpoint proteins or receptors include without limitation CD274 (CD274, PDL1, PD-L1); programmed cell death 1 ligand 2 (PDCD1LG2, PD- L2, CD273); programmed cell death 1 (PDCD1, PD1, PD-1); cytotoxic T-lymphocyte associated protein 4 (CTLA4, CD152); CD276 (B7H3); V-set domain containing T cell activation inhibitor 1 (VTCN1, B7H4); V-set immunoregulatory receptor (VSIR, B7H5, VISTA); immunoglobulin superfamily member 11 (IGSF11, VSIG3); TNFRSF14 (HVEM, CD270), TNFSF14 (HVEML); CD272 (B and T lymphocyte associated (BTLA)); PVR related immunoglobulin domain containing (PVRIG, CD112R); T cell immunoreceptor with Ig and ITIM domains (TIGIT); lymphocyte activating 3 (LAG3, CD223); hepatitis A virus cellular receptor 2 (HAVCR2, TIMD3, TIM3); galectin 9 (LGALS9); killer cell immunoglobulin like receptor, three Ig domains and long cytoplasmic tail 1 (KIR, CD158E1); killer cell immunoglobulin like receptor, two Ig domains and long cytoplasmic tail 1 (KIR2DL1); killer cell immunoglobulin like receptor, two Ig domains and long cytoplasmic tail 2 (KIR2DL2); killer cell immunoglobulin like receptor, two Ig domains and long cytoplasmic tail 3 (KIR2DL3); and killer cell immunoglobulin like receptor, three Ig domains and long cytoplasmic tail 1 (KIR3DL1). In various embodiments, the agents, as described herein, are combined with one or more agonist or activators of one or more T-cell stimulatory immune checkpoint proteins or receptors. Illustrative T-cell stimulatory immune checkpoint proteins or receptors include without limitation CD27, CD70; CD40, CD40LG; inducible T cell costimulator (ICOS, CD278); inducible T cell costimulator ligand (ICOSLG, B7H2); TNF receptor superfamily member 4 (TNFRSF4, 0X40); TNF superfamily member 4 (TNFSF4, OX40L); TNFRSF9 (CD137), TNFSF9 (CD137L); TNFRSF18 (GITR), TNFSF18 (GITRL); CD80 (B7-1), CD28; nectin cell adhesion molecule 2 (NECTIN2, CD112); CD226 (DNAM-1); CD244 (2B4, SLAMF4), Poliovirus receptor (PVR) cell adhesion molecule (PVR, CD155). See, e.g., Xu et al., J Exp Clin Cancer Res. (2018) 37:110.

[0164] In various embodiments, the agents as described herein, are combined with one or more blockers or inhibitors of one or more NK-cell inhibitory immune checkpoint proteins or receptors. Illustrative NK-cell inhibitory immune checkpoint proteins or receptors include without limitation killer cell immunoglobulin like receptor, three Ig domains and long cytoplasmic tail 1 (KIR, CD158E1); killer cell immunoglobulin like receptor, two Ig domains and long cytoplasmic tail 1 (KIR2DL1); killer cell immunoglobulin like receptor, two Ig domains and long cytoplasmic tail 2 (KIR2DL2); killer cell immunoglobulin like receptor, two Ig domains and long cytoplasmic tail 3 (KIR2DL3); killer cell immunoglobulin like receptor, three Ig domains and long cytoplasmic tail 1 (KIR3DL1); killer cell lectin like receptor Cl (KLRC1, NKG2A, CD159A); and killer cell lectin like receptor DI (KLRD1, CD94). In various embodiments, the agents as described herein, are combined with one or more agonist or activators of one or more NK-cell stimulatory immune checkpoint proteins or receptors. Illustrative NK-cell stimulatory immune checkpoint proteins or receptors include without limitation CD16, CD226 (DNAM-1); CD244 (2B4, SLAMF4); killer cell lectin like receptor KI (KLRK1, NKG2D, CD314); SLAM family member 7 (SLAMF7). See, e.g., Davis et al., Semin Immunol. (2017) 31:64-75; Fang et al., Semin Immunol. (2017) 31:37-54; and Chiossone et al., Nat Rev Immunol. (2018) 18(11):671-688.

[0165] In some embodiments, the one or more immune checkpoint inhibitors comprises a proteinaceous (e.g., antibody or fragment thereof, or antibody mimetic) inhibitor of PD-L1 (CD274), PD-1 (PDCD1) or CTLA4. In some embodiments, the one or more immune checkpoint inhibitors comprises a small organic molecule inhibitor of PD-L1 (CD274), PD-1 (PDCD1) or CTLA4. In some embodiments, the small molecule inhibitor of CD274 or PDCD1 is selected from the group consisting of GS-4224, GS-4416, INCB086550 and MAX10181. In some embodiments, the small molecule inhibitor of CTLA4 comprises BPI-002.

[0166] Examples of inhibitors of CTLA4 that can be co-administered include without limitation ipilimumab, tremelimumab, BMS-986218, AGEN1181, AGEN1884, BMS-986249, MK-1308, REGN-4659, ADU-1604, CS-1002, BCD-145, APL-509, JS-007, BA-3071, ONC- 392, AGEN-2041, JHL-1155, KN-044, CG-0161, ATOR-1144, PBL5D3H5, BPI-002, as well as multi-specific inhibitors FPT-155 (CTLA4/PD-L1/CD28), PF-06936308 (PD-1/ CTLA4), MGD-019 (PD-1/CTLA4), KN-046 (PD-1/CTLA4), MEDI-5752 (CTLA4/PD-1), XmAb-20717 (PD-1/CTLA4), and AK-104 (CTLA4/PD-1).

[0167] Examples of inhibitors of PD-L1 (CD274) or PD-1 (PDCD1) that can be coadministered include without limitation pembrolizumab, nivolumab, cemiplimab, pidilizumab, AMP-224, MEDI0680 (AMP-514), spartalizumab, atezolizumab, avelumab, durvalumab, BMS- 936559, CK-301, PF-06801591, BGB-A317 (tislelizumab), GLS-010 (WBP-3055), AK-103 (HX-008), AK-105, CS-1003, HLX-10, MGA-012, BI-754091, AGEN-2034, JS-001 (toripalimab), JNJ-63723283, genolimzumab (CBT-501), LZM-009, BCD-100, LY-3300054, SHR-1201, SHR-1210 (camrelizumab), Sym-021, ABBV-181(budigalimab), PD1-PIK, BAT- 1306, (MSB0010718C), CX-072, CBT-502, TSR-042 (dostarlimab), MSB-2311, JTX-4014, BGB-A333, SHR-1316, CS-1001 (WBP-3155, KN-035, IBI-308 (sintilimab), HLX-20, KL- A167, STI-A1014, STI-A1015 (IMC-001), BCD-135, FAZ-053, TQB-2450, MDX1105-01, GS- 4224, GS-4416, INCB086550, MAX10181, as well as multi- specific inhibitors FPT-155 (CTLA4/PD-L1/CD28), PF-06936308 (PD-1/ CTLA4), MGD-013 (PD-l/LAG-3), FS-118 (LAG-3/PD-L1) MGD-019 (PD-1/CTLA4), KN-046 (PD-1/CTLA4), MEDI-5752 (CTLA4/PD- 1), RO-7121661 (PD-l/TIM-3), XmAb-20717 (PD-1/CTLA4), AK-104 (CTLA4/PD-1), M7824 (PD-L1/TGFP-EC domain), CA-170 (PD-L1/VISTA), CDX-527 (CD27/PD-L1), LY-3415244 (TIM3/PDL1), and INBRX-105 (4-1BB/PDL1).

[0168] In various embodiments, the agents as described herein are combined with anti- TIGIT antibodies, such as BMS-986207, RG-6058, and AGEN-1307.

TNF Receptor Superfamily (TNFRSF) Member Agonists or Activators

[0169] In various embodiments, the agents as described herein are combined with an agonist of one or more TNF receptor superfamily (TNFRSF) members, e.g., an agonist of one or more of TNFRSF1 A (NCBT Gene ID: 7132), TNFRSF1B (NCBT Gene ID: 7133), TNFRSF4 (0X40, CD134; NCBI Gene ID: 7293), TNFRSF5 (CD40; NCBI Gene ID: 958), TNFRSF6 (FAS, NCBI Gene ID: 355), TNFRSF7 (CD27, NCBI Gene ID: 939), TNFRSF8 (CD30, NCBI Gene ID: 943), TNFRSF9 (4-1BB, CD137, NCBI Gene ID: 3604), TNFRSF10A (CD261, DR4, TRAILR1, NCBI Gene ID: 8797), TNFRSF10B (CD262, DR5, TRAILR2, NCBI Gene ID: 8795), TNFRSF10C (CD263, TRAILR3, NCBI Gene ID: 8794), TNFRSF10D (CD264, TRAILR4, NCBI Gene ID: 8793), TNFRSF11A (CD265, RANK, NCBI Gene ID: 8792), TNFRSF11B (NCBI Gene ID: 4982), TNFRSF12A (CD266, NCBI Gene ID: 51330), TNFRSF13B (CD267, NCBI Gene ID: 23495), TNFRSF13C (CD268, NCBI Gene ID: 115650), TNFRSF16 (NGFR, CD271, NCBI Gene ID: 4804), TNFRSF17 (BCMA, CD269, NCBI Gene ID: 608), TNFRSF18 (GITR, CD357, NCBI Gene ID: 8784), TNFRSF19 (NCBI Gene ID: 55504), TNFRSF21 (CD358, DR6, NCBI Gene ID: 27242), and TNFRSF25 (DR3, NCBI Gene ID: 8718).

[0170] Examples of anti-TNFRSF4 (0X40) antibodies that can be co-administered include without limitation, MEDI6469, MED 16383, MED 10562 (tavolixizumab), MOXR0916, PF-04518600, RG-7888, GSK-3174998, INCAGN1949, BMS-986178, GBR-8383, ABBV-368, and those described in WO2016179517, WO2017096179, WO2017096182, WO2017096281, and WO2018089628.

[0171] Examples of anti-TNFRSF5 (CD40) antibodies that can be co-administered include without limitation RG7876, SEA-CD40, APX-005M and ABBV-428.

[0172] In some embodiments, the anti-TNFRSF7 (CD27) antibody varlilumab (CDX- 1127) is co-administered.

[0173] Examples of anti-TNFRSF9 (4-1BB, CD137) antibodies that can be coadministered include without limitation urelumab, utomilumab (PF-05082566), AGEN2373 and ADG-106.

[0174] Examples of anti-TNFRSF18 (GITR) antibodies that can be co-administered include without limitation, MEDI1873, FPA-154, INCAGN-1876, TRX-518, BMS-986156, MK-1248, GWN-323, and those described in WO2017096179, WO2017096276, WO2017096189, and WO2018089628. In some embodiments, an antibody, or fragment thereof, co-targeting TNFRSF4 (0X40) and TNFRSF18 (GITR) is co-administered. Such antibodies are described, e.g., in WO2017096179 and WO2018089628.

Bi-and Tri-Speciflc Natural Killer (NK)-Cell Engagers

[0175] In various embodiments, the agents as described herein, are combined with a bispecific NK-cell engager (BiKE) or a tri-specific NK-cell engager (TriKE) (e.g., not having an Fc) or bi-specific antibody (e.g., having an Fc) against an NK cell activating receptor, e.g., CD16A, C-type lectin receptors (CD94/NKG2C, NKG2D, NKG2E/H and NKG2F), natural cytotoxicity receptors (NKp30, NKp44 and NKp46), killer cell C-type lectin-like receptor (NKp65, NKp80), Fc receptor FcyR (which mediates antibody-dependent cell cytotoxicity), SLAM family receptors (e.g., 2B4, SLAM6 and SLAM7), killer cell immunoglobulin- like receptors (KIR) (KIR-2DS and KIR-3DS), DNAM-1 and CD137 (41BB). As appropriate, the anti-CD16 binding bi-specific molecules may or may not have an Fc. Illustrative bi-specific NK-cell engagers that can be co-administered target CD 16 and one or more HIV-associated antigens as described herein. BiKEs and TriKEs are described, e.g., in Felices et al., Methods Mol Biol. (2016) 1441:333—346; Fang et al., Semin Immunol. (2017) 31:37-54. Examples of trispecific NK cell engagers (TRiKE) include, but are not limited to, OXS-3550, HIV-TriKE, and CD16-IL-15-B7H3 TriKe.

Indoleamine-pyrrole-2,3-dioxygenase (IDO1 ) inhibitors

[0176] In various embodiments, the agents as described herein are combined with an inhibitor of indoleamine 2,3-dioxygenase 1 (IDO1; NCBI Gene ID: 3620). Examples of IDO1 inhibitors include without limitation, BLV-0801, epacadostat, F-001287, GBV-1012, GBV- 1028, GDC-0919, indoximod, NKTR-218, NLG-919-based vaccine, PF-06840003, pyranonaphthoquinone derivatives (SN-35837), resminostat, SBLK-200802, BMS-986205, shlDO-ST, EOS-200271, KHK-2455, and LY-3381916.

Toll-Like Receptor (TLR) Agonists

[0177] In various embodiments, the agents as described herein are combined with an agonist of a toll-like receptor (TLR), e.g., an agonist of TLR1 (NCBI Gene ID: 7096), TLR2 (NCBI Gene ID: 7097), TLR3 (NCBI Gene ID: 7098), TLR4 (NCBI Gene ID: 7099), TLR5 (NCBI Gene ID: 7100), TLR6 (NCBI Gene ID: 10333), TLR7 (NCBI Gene ID: 51284), TLR8 (NCBI Gene ID: 51311), TLR9 (NCBI Gene ID: 54106), and/or TLR10 (NCBI Gene ID: 81793). Example TLR7 agonists that can be co-administered include without limitation AL-034, DSP-0509, GS-9620 (vesatolimod), vesatolimod analog, LHC-165, TMX-101 (imiquimod), GSK-2245035, resiquimod, DSR-6434, DSP-3025, IMO-4200, MCT-465, MEDL9197, 3M- 051, SB-9922, 3M-052, Limtop, TMX-30X, TMX-202, RG-7863, RG-7854, RG-7795, and the compounds disclosed in US20100143301 (Gilead Sciences), US20110098248 (Gilead

Sciences), and US20090047249 (Gilead Sciences), US20140045849 (Janssen), US20140073642 (Janssen), WO2014/056953 (Janssen), WO2014/076221 (Janssen), WO2014/128189 (Janssen), US20140350031 (Janssen), WO2014/023813 (Janssen), US20080234251 (Array Biopharma), US20080306050 (Array Biopharma), US20100029585 (Ventirx Pharma), US20110092485 (Ventirx Pharma), US20110118235 (Ventirx Pharma), US20120082658 (Ventirx Pharma), US20120219615 (Ventirx Pharma), US20140066432 (Ventirx Pharma), US20140088085 (Ventirx Pharma), US20140275167 (Novira Therapeutics), and US20130251673 (Novira Therapeutics). TLR7/TLR8 agonists include without limitation NKTR-262, telratolimod and BDB-001. TLR8 agonists include without limitation E-6887, IMO-4200, IMO-8400, IMO-9200, MCT-465, MEDI-9197, motolimod, resiquimod, GS-9688, VTX-1463, VTX-763, 3M-051, 3M- 052, and the compounds disclosed in US20140045849 (Janssen), US20140073642 (Janssen), WO2014/056953 (Janssen), WO2014/076221 (Janssen), WO2014/128189 (Janssen), US20140350031 (Janssen), WO2014/023813 (Janssen), US20080234251 (Array Biopharma), US20080306050 (Array Biopharma), US20100029585 (Ventirx Pharma), US20110092485 (Ventirx Pharma), US20110118235 (Ventirx Pharma), US20120082658 (Ventirx Pharma), US20120219615 (Ventirx Pharma), US20140066432 (Ventirx Pharma), US20140088085 (Ventirx Pharma), US20140275167 (Novira Therapeutics), and US20130251673 (Novira Therapeutics). TLR9 agonists include without limitation AST-008, cobitolimod, CMP-001, IMO-2055, IMO-2125, S-540956, litenimod, MGN-1601, BB-001, BB-006, IMO-3100, IMO- 8400, IR-103, IMO-9200, agatolimod, DIMS-9054, DV-1079, DV-1179, AZD-1419, lefitolimod (MGN-1703), CYT-003, CYT-003-QbG10, tilsotolimod and PUL-042. Examples of TLR3 agonist include rintatolimod, poly-ICLC, RIBOXXON®, Apoxxim, RIBOXXIM®, IPH- 33, MCT-465, MCT-475, and ND-1.1. TLR4 agonists include, but are not limited to, G-100 and GSK-1795091.

CDK inhibitors or antagonists

[0178] In some embodiments, the agents described herein are combined with an inhibitor or antagonist of CDK. In some embodiments, the CDK inhibitor or antagonist is selected from the group consisting of VS2-370.

STING agonists, RIG-I and NOD2 modulators

[0179] In some embodiments, the agents described herein are combined with a stimulator of interferon genes (STING). In some embodiments, the STING receptor agonist or activator is selected from the group consisting of ADU-S100 (MIW-815), SB-11285, MK-1454, SR-8291, AdVCA0848, GSK-532, SYN-STING, MSA-1, SR-8291, STING agonist (latent HIV), 5,6-dimethylxanthenone-4-acetic acid (DMXAA), cyclic-GAMP (cGAMP) and cyclic-di- AMP. In some embodiments, the agents described herein are combined with a RIG-I modulator such as RGT-100, or NOD2 modulator, such as SB-9200, and IR-103. LAG-3 and TIM-3 inhibitors

[0180] In certain embodiments, the agents as described herein are combined with an anti-TIM-3 antibody, such as TSR-022, LY-3321367, MBG-453, INCAGN-2390.

[0181] In certain embodiments, the antibodies or antigen-binding fragments described herein are combined with an anti LAG-3 (Lymphocyte- activation) antibody, such as relatlimab (ONO-4482), LAG-525, MK-4280, REGN-3767, INCAGN2385.

Interleukin agonists

[0182] In certain embodiments, the agents described herein are combined with an interleukin agonist, such as IL-2, IL-7, IL-15, IL-10, IL-12 agonists; examples of IL-2 agonists such as proleukin (aldesleukin, IL-2); BC-IL (Cel-Sci), pegylated IL-2 (e.g., NKTR-214); modified variants of IL-2 (e.g., THOR-707), bempegaldesleukin, AIC-284, ALKS-4230, CUI- 101, Neo-2/15; examples of IL-15 agonists, such as ALT-803, NKTR-255, and hetIL-15, interleukin- 15/Fc fusion protein, AM-0015, NIZ-985, SO-C101, IL-15 Synthorin (pegylated II- 15), P-22339, and a IL-15 -PD-1 fusion protein N-809; examples of IL-7 include without limitation CYT-107.

[0183] Examples of additional immune-based therapies that can be combined with an agent of this disclosure include, but are not limited to, interferon alfa, interferon alfa-2b, interferon alfa-n3, pegylated interferon alfa, interferon gamma; FLT3 agonists such as CDX- 301, GS-3583, gepon, normferon, peginterferon alfa-2a, peginterferon alfa- 2b, and RPLMN.

Phosphatidylinositol 3-kinase (PI3K) Inhibitors

[0184] Examples of PI3K inhibitors include, but are not limited to, idelalisib, alpelisib, buparlisib, CAI orotate, copanlisib, duvelisib, gedatolisib, neratinib, panulisib, perifosine, pictilisib, pilaralisib, puquitinib mesylate, rigosertib, rigosertib sodium, sonolisib, taselisib, AMG-319, AZD-8186, BAY-1082439, CLR-1401, CLR-457, CUDC-907, DS-7423, EN-3342, GSK-2126458, GSK-2269577, GSK-2636771, INCB-040093, LY-3023414, MLN-1117, PQR- 309, RG-7666, RP-6530, RV-1729, SAR-245409, SAR-260301, SF-1126, TGR-1202, UCB- 5857, VS-5584, XL-765, and ZSTK-474.

alpha 4/beta 7 ntagonists [0185] Examples of Integrin alpha-4/beta-7 antagonists include, but are not limited to, PTG-100, TRK-170, abrilumab, etrolizumab, carotegrast methyl, and vedolizumab. HPK1 Inhibitors [0186] Examples of HPK1 inhibitors include, but are not limited to, ZYF-0272, and ZYF-0057. HIV Targeting Antibodies [0187] Examples of HIV antibodies, bispecific antibodies, and “antibody-like” therapeutic proteins include, but are not limited to, DARTs®, DUOBODIES®, BITES®, XmAbs®, TandAbs®, Fab derivatives, bNAbs (broadly neutralizing HIV-1 antibodies), TMB- 360, TMB-370, and those targeting HIV gp120 or gp41, antibody-Recruiting Molecules targeting HIV, anti-CD63 monoclonal antibodies, anti-GB virus C antibodies, anti-GP120/CD4, gp120 bispecific monoclonal antibody, CCR5 bispecific antibodies, anti-Nef single domain antibodies, anti-Rev antibody, camelid derived anti-CD18 antibodies, camelid-derived anti- ICAM-1 antibodies, DCVax-001, gp140 targeted antibodies, gp41-based HIV therapeutic antibodies, human recombinant mAbs (PGT-121), PGT121.414.LS, ibalizumab, ibalizumab (second generation), Immuglo, MB-66, clone 3 human monoclonal antibody targeting KLIC (HIV infection), GS-9721, BG-HIV, VRC-HIVMAB091-00-AB. [0188] Various bNAbs may be used. Examples include, but are not limited to, those described in U.S. Patent No.8673307, 9,493,549, 9,783,594, 10,239,935, US2018371086, US2020223907, WO2014/063059, WO2012/158948, WO2015/117008, and PCT/US2015/41272, and WO2017/096221, including antibodies 12A12, 12A21, NIH45-46, bANC131, 8ANC134, IB2530, INC9, 8ANC195.8ANC196, 10-259, 10-303, 10-410, 10- 847, 10-996, 10-1074, 10-1121, 10-1130, 10-1146, 10-1341, 10-1369, and 10-1074GM. Additional examples include those described in Klein et al., Nature, 492(7427): 118-22 (2012), Horwitz et al., Proc Natl Acad Sci U S A, 110(41): 16538-43 (2013), Scheid et al., Science, 333 : 1633-1637 (2011), Scheid et al., Nature, 458:636-640 (2009), Eroshkin et al, Nucleic Acids Res., 42 (Database issue):Dl 133-9 (2014), Mascola et al., Immunol Rev., 254(l):225-44 (2013), such as 2F5, 4E10, M66.6, CAP206-CH12, 10E81 (all of which bind the MPER of gp41); PG9, PG16, CH01-04 (all of which bind V1V2-glycan), 2G12 (which binds to outer domain glycan); b12, 58

J 6, C 03 06, V C0 03, V C G0 , 0 b, V C C 303 , 3 NC6 , 3 NC89, 3 NC9 , 3BNC95, 3BNC104, 3BNC176, and 8ANC131 (all of which bind to the CD4 binding site). [0189] Additional broadly neutralizing antibodies that can be used as a second therapeutic agent in a combination therapy are described, e.g., in U.S. Patent Nos.8,673,307; 9,493,549; 9,783,594; and WO 2012/154312; WO2012/158948; WO 2013/086533; WO 2013/142324; WO2014/063059; WO 2014/089152, WO 2015/048462; WO 2015/103549; WO 2015/117008; WO2016/014484; WO 2016/154003; WO 2016/196975; WO 2016/149710; WO2017/096221; WO 2017/133639; WO 2017/133640, which are hereby incorporated herein by reference in their entireties for all purposes. Additional examples include, but are not limited to, those described in Sajadi et al., Cell. (2018) 173(7):1783-1795; Sajadi et al., J Infect Dis. (2016) 213(1):156-64; Klein et al., Nature, 492(7427): 118-22 (2012), Horwitz et al., Proc Natl Acad Sci U S A, 110(41): 16538-43 (2013), Scheid et al., Science, 333: 1633-1637 (2011), Scheid et al., Nature, 458:636-640 (2009), Eroshkin et al., Nucleic Acids Res., 42 (Database issue):Dl 133-9 (2014), Mascola et al., Immunol Rev., 254(l):225-44 (2013), such as 2F5, 4E10, M66.6, CAP206-CH12, 10E8, 10E8v4, 10E8-5R-100cF, DH511.11P, 7b2, 10-1074, and LN01 (all of which bind the MPER of gp41). [0190] Examples of additional antibodies include, but are not limited to, bavituximab, UB-421, BF520.1, BiIA-SG, CH01, CH59, C2F5, C4E10, C2F5+C2G12+C4E10, CAP256V2LS, 3BNC117, 3BNC117-LS, 3BNC60, DH270.1, DH270.6, D1D2, 10-1074-LS, Cl3hmAb, GS-9722 (elipovimab), DH411-2, BG18, GS-9721, GS-9723, PGT145, PGT121, PGT-121.60, PGT-121.66, PGT122, PGT-123, PGT-124, PGT-125, PGT-126, PGT-151, PGT- 130, PGT-133, PGT-134, PGT-135, PGT-128, PGT-136, PGT-137, PGT-138, PGT-139, MDX010 (ipilimumab), DH511, DH511-2, N6, N6LS, N49P6, N49P7, N49P7.1, N49P9, N49P11, N60P1.1, N60P25.1, N60P2.1, N60P31.1, N60P22, NIH 45-46, PGC14, PGG14, PGT-142, PGT-143, PGT-144, PGDM1400, PGDM12, PGDM21, PCDN-33A, 2Dm2m, 4Dm2m, 6Dm2m, PGDM1400, MDX010 (ipilimumab), VRC01, VRC-01-LS, A32, 7B2, 10E8, VRC-07-523, VRC07-523LS, VRC24, VRC41.01, 10E8VLS, 3810109, 10E8v4, IMC-HIV, iMabm36, eCD4-Ig, IOMA, CAP256-VRC26.25, DRVIA7,VRC-HIVMAB080-00-AB, VRC- HIVMAB060-00-AB, P2G12, VRC07, 354BG8, 354BG18, 354BG42, 354BG33, 354BG129, 354BG188, 354BG411, 354BG426, VRC29.03, CAP256, CAP256-VRC26.08, CAP256- VRC26.09, CAP256-VRC26.25, PCT64-24E and VRC38.01, PGT-151, CAP248-2B, 35O22, ACS202, VRC34 and VRC34.01, 10E8, 10E8v4, 10E8-5R-100cF, 4E10, DH511.11P, 2F5, 7b2, 59

a d N0 . [0191] Examples of HIV bispecific and trispecific antibodies include without limitation MGD014, B12BiTe, BiIA-SG, TMB-bispecific, SAR-441236, VRC-01/PGDM-1400/10E8v4, 10E8.4/iMab, 10E8v4/PGT121-VRC01. [0192] Examples of in vivo delivered bNAbs include without limitation AAV8-VRC07; mRNA encoding anti-HIV antibody VRC01; and engineered B-cells encoding 3BNC117 (Hartweger et al., J. Exp. Med.2019, 1301). Pharmacokinetic Enhancers [0193] Examples of pharmacokinetic enhancers include, but are not limited to, cobicistat and ritonavir. Additional Therapeutic Agents [0194] Examples of additional therapeutic agents include, but are not limited to, the compounds disclosed in WO 2004/096286 (Gilead Sciences), WO 2006/015261 (Gilead Sciences), WO 2006/110157 (Gilead Sciences), WO 2012/003497 (Gilead Sciences), WO 2012/003498 (Gilead Sciences), WO 2012/145728 (Gilead Sciences), WO 2013/006738 (Gilead Sciences), WO 2013/159064 (Gilead Sciences), WO 2014/100323 (Gilead Sciences), US 2013/0165489 (University of Pennsylvania), US 2014/0221378 (Japan Tobacco), US 2014/0221380 (Japan Tobacco), WO 2009/062285 (Boehringer Ingelheim), WO 2010/130034 (Boehringer Ingelheim), WO 2013/006792 (Pharma Resources), US 20140221356 (Gilead Sciences), US 20100143301 (Gilead Sciences) and WO 2013/091096 (Boehringer Ingelheim). HIV Vaccines [0195] Examples of HIV vaccines include, but are not limited to, peptide vaccines, recombinant subunit protein vaccines, live vector vaccines, DNA vaccines, HIV MAG DNA vaccine, CD4-derived peptide vaccines, vaccine combinations, adenoviral vector vaccines (an adenoviral vector such as Ad5, Ad26 or Ad35), simian adenovirus (chimpanzee, gorilla, rhesus i.e. rhAd), adeno-associated virus vector vaccines, Chimpanzee adenoviral vaccines (e.g., ChAdOX1, ChAd68, ChAd3, ChAd63, ChAd83, ChAd155, ChAd157, Pan5, Pan6, Pan7, Pan9), Coxsackieviruses based vaccines, enteric virus based vaccines, Gorilla adenovirus vaccines, 60

e t v a vecto based vacc e, a e av us vacc es (suc as C V, c de), b seg e ted o tri-segmented arenavirus based vaccine, trimer-based HIV-1 vaccine, measles virus based vaccine, flavivirus vector based vaccines, tobacco mosaic virus vector based vaccine, Varicella- zoster virus based vaccine, Human parainfluenza virus 3 (PIV3) based vaccines, poxvirus based vaccine (modified vaccinia virus Ankara (MVA), orthopoxvirus-derived NYVAC, and avipoxvirus-derived ALVAC (canarypox virus) strains); fowlpox virus based vaccine, rhabdovirus-based vaccines, such as VSV and marabavirus; recombinant human CMV (rhCMV) based vaccine, alphavirus-based vaccines, such as semliki forest virus, venezuelan equine encephalitis virus and sindbis virus; (see Lauer, Clinical and Vaccine Immunology, 2017, DOI: 10.1128/CVI.00298-16); LNP formulated mRNA based therapeutic vaccines; LNP- formulated self-replicating RNA/self-amplifying RNA vaccines. [0196] Examples of vaccines include: AAVLP-HIV vaccine, AE-298p, anti-CD40.Env- gp140 vaccine, Ad4-EnvC150, BG505 SOSIP.664 gp140 adjuvanted vaccine, BG505 SOSIP.GT1.1 gp140 adjuvanted vaccine, ChAdOx1.tHIVconsv1 vaccine, CMV-MVA triplex vaccine, ChAdOx1.HTI, Chimigen HIV vaccine, ConM SOSIP.v7 gp140, ALVAC HIV (vCP1521), AIDSVAX B/E (gp120), monomeric gp120 HIV-1 subtype C vaccine, MPER-656 liposome subunit vaccine, Remune, ITV-1, Contre Vir, Ad5-ENVA-48, DCVax-001 (CDX- 2401), Vacc-4x, Vacc-C5, VAC-3S, multiclade DNA recombinant adenovirus-5 (rAd5), rAd5 gag-pol env A/B/C vaccine, Pennvax-G, Pennvax-GP, Pennvax-G/MVA-CMDR, HIV-TriMix- mRNA vaccine, HIV-LAMP-vax, Ad35, Ad35-GRIN, NAcGM3/VSSP ISA-51, poly-ICLC adjuvanted vaccines, TatImmune, GTU-multiHIV (FIT-06), ChAdV63.HIVconsv, gp140[delta]V2.TV1+MF-59, rVSVIN HIV-1 gag vaccine, SeV-EnvF, SeV-Gag vaccine, AT- 20, DNK-4, ad35-Grin/ENV, TBC-M4, HIVAX, HIVAX-2, N123-VRC-34.01 inducing epitope-based HIV vaccine, NYVAC-HIV-PT1, NYVAC-HIV-PT4, DNA-HIV-PT123, rAAV1-PG9DP, GOVX-B11, GOVX-B21, GOVX-C55, TVI-HIV-1, Ad-4 (Ad4-env Clade C+Ad4-mGag), Paxvax, EN41-UGR7C, EN41-FPA2, ENOB-HV-11, ENOB-HV-12, PreVaxTat, AE-H, MYM-V101, CombiHIVvac, ADVAX, MYM-V201, MVA-CMDR, MagaVax, DNA-Ad5 gag/pol/nef/nev (HVTN505), MVATG-17401, ETV-01, CDX-1401, DNA and Sev vectors vaccine expressing SCaVII, rcAD26.MOS1.HIV-Env, Ad26.Mod.HIV vaccine, Ad26.Mod.HIV + MVA mosaic vaccine + gp140, AGS-004, AVX-101, AVX-201, PEP-6409, SAV-001, ThV-01, TL-01, TUTI-16, VGX-3300, VIR-1111, IHV-001, and virus-like particle vaccines such as pseudovirion vaccine, CombiVICHvac, LFn-p24 B/C fusion vaccine, GTU- based DNA vaccine, HIV gag/pol/nef/env DNA vaccine, anti-TAT HIV vaccine, conjugate 61 polypeptides vaccine, dendritic-cell vaccines (such as DermaVir), gag-based DNA vaccine, GI- 2010, gp41 HIV-1 vaccine, HIV vaccine (PIKA adjuvant), i-key/MHC class II epitope hybrid peptide vaccines, ITV-2, ITV-3, ITV-4, LIPO-5, multiclade Env vaccine, MVA vaccine, Pennvax-GP, pp71 -deficient HCMV vector HIV gag vaccine, rgpl60 HIV vaccine, RN Active HIV vaccine, SCB-703, Tat Oyi vaccine, TBC-M4, UBI HIV gpl20, Vacc-4x + romidepsin, variant gpl20 polypeptide vaccine, rAd5 gag-pol env A/B/C vaccine, DNA.HTI and MVA.HTI, VRC-HIVDNA016-00-VP + VRC-HIVADVO 14-00- VP, INO-6145, INJ-9220, gp!45 C.6980; eOD-GT8 60mer based vaccine, PD-201401, env (A, B, C, A/E)/gag (C) DNA Vaccine, gpl20 (A,B,C,A/E) protein vaccine, PDPHV-201401, Ad4-EnvCN54, EnvSeq-1 Envs HIV-1 vaccine (GLA-SE adjuvanted), HIV p24gag prime-boost plasmid DNA vaccine, HIV-1 iglbl2 neutralizing VRC-01 antibody-stimulating anti-CD4 vaccine, arenavirus vector-based vaccines (Vaxwave, TheraT), MVA-BN HIV-1 vaccine regimen, mRNA based prophylactic vaccines, VPI-211, multimeric HIV gpl20 vaccine (Fred Hutchinson cancer center), TBL-1203HI, CH505 TF chTrimer, CD40.HIVRI.Env vaccine, Drep-HIV-PT-1, mRNA-1644, and mRNA-1574.

Birth Control (Contraceptive) Combination Therapy

[0197] In certain embodiments, the agents described herein are combined with a birth control or contraceptive regimen. Therapeutic agents used for birth control (contraceptive) that can be combined with an agent of this disclosure include without limitation cyproterone acetate, desogestrel, dienogest, drospirenone, estradiol valerate, ethinyl Estradiol, ethynodiol, etonogestrel, levomefolate, levonorgestrel, lynestrenol, medroxyprogesterone acetate, mestranol, mifepristone, misoprostol, nomegestrol acetate, norelgestromin, norethindrone, noretynodrel, norgestimate, ormeloxifene, segestersone acetate, ulipristal acetate, and any combinations thereof.

[0198] In a particular embodiment, a compound disclosed herein, or a pharmaceutically acceptable salt thereof, is combined with one, two, three, or four additional therapeutic agents selected from ATRIPLA® (efavirenz, tenofovir disoproxil fumarate, and emtricitabine); COMPLERA® (EVIPLERA®; rilpivirine, tenofovir disoproxil fumarate, and emtricitabine); STR1B1LD® (elvitegravir, cobicistat, tenofovir disoproxil fumarate, and emtricitabine); TRUVADA® (tenofovir disoproxil fumarate and emtricitabine; TDF +FTC); DESCO VY® (tenofovir alafenamide and emtricitabine); ODEFSEY® (tenofovir alafenamide, emtricitabine, and rilpivirine); GENVOYA® (tenofovir alafenamide, emtricitabine, cobicistat, and elvitegravir); BIKT AR VY® (bictegravir + emtricitabine + tenofovir alafenamide), adefovir; adefovir dipivoxil; cobicistat; emtricitabine; tenofovir; tenofovir alafenamide and elvitegravir; tenofovir alafenamide + elvitegravir (rectal formulation, HIV infection); tenofovir disoproxil; tenofovir disoproxil fumarate; tenofovir alafenamide; tenofovir alafenamide hemifumarate; TRIUMEQ® (dolutegravir, abacavir, and lamivudine); dolutegravir, abacavir sulfate, and lamivudine; raltegravir; PEGylated raltegravir; raltegravir and lamivudine; lamivudine+lopinavir+ritonavir+abacavir; maraviroc; tenofovir + emtricitabine + maraviroc, enfuvirtide; ALUVIA® (KALETRA®; lopinavir and ritonavir); COMBIVIR® (zidovudine and lamivudine; AZT+3TC); EPZICOM® (LIVEXA®; abacavir sulfate and lamivudine; ABC+3TC); TRIZIVIR® (abacavir sulfate, zidovudine, and lamivudine; ABC+AZT+3TC); rilpivirine; rilpivirine hydrochloride; atazanavir sulfate and cobicistat; atazanavir and cobicistat; darunavir and cobicistat; atazanavir; atazanavir sulfate; dolutegravir; elvitegravir; ritonavir; atazanavir sulfate and ritonavir; darunavir; lamivudine; prolastin; fosamprenavir; fosamprenavir calcium efavirenz; etravirine; nelfinavir; nelfinavir mesylate; interferon; didanosine; stavudine; indinavir; indinavir sulfate; tenofovir and lamivudine; zidovudine; nevirapine; saquinavir; saquinavir mesylate; aldesleukin; zalcitabine; tipranavir; amprenavir; delavirdine; delavirdine mesylate; Radha-108 (receptol); lamivudine and tenofovir disoproxil fumarate; efavirenz, lamivudine, and tenofovir disoproxil fumarate; phosphazid; lamivudine, nevirapine, and zidovudine; abacavir; and abacavir sulfate.

[0199] In some embodiments, an agent disclosed herein, or a pharmaceutical composition thereof, is combined with an HIV nucleoside or nucleotide inhibitor of reverse transcriptase and an HIV non-nucleoside inhibitor of reverse transcriptase. In another specific embodiment, an agent disclosed herein, or a pharmaceutical composition thereof, is combined with an HIV nucleoside or nucleotide inhibitor of reverse transcriptase, and an HIV protease inhibiting compound. In an additional embodiment, an agent disclosed herein, or a pharmaceutical composition thereof, is combined with an HIV nucleoside or nucleotide inhibitor of reverse transcriptase, an HIV non-nucleoside inhibitor of reverse transcriptase, and a pharmacokinetic enhancer. In certain embodiments, an agent disclosed herein, or a pharmaceutical composition thereof, is combined with at least one HIV nucleoside inhibitor of reverse transcriptase, an integrase inhibitor, and a pharmacokinetic enhancer. In another embodiment, an agent disclosed herein, or a pharmaceutical composition thereof, is combined with two HIV nucleoside or nucleotide inhibitors of reverse transcriptase. [0200] In another embodiment, an agent disclosed herein, or a pharmaceutical composition thereof, is combined with a first additional therapeutic agent chosen from dolutegravir, cabotegravir, darunavir, bictegravir, elsulfavirine, rilpivirine, and lenacapavir and a second additional therapeutic agent chosen from emtricitabine and lamivudine.

[0201] In some embodiments, an agent disclosed herein, or a pharmaceutical composition thereof, is combined with a first additional therapeutic agent (a contraceptive) selected from the group consisting of cyproterone acetate, desogestrel , dienogest, drospirenone, estradiol valerate, ethinyl Estradiol, ethynodiol, etonogestrel, levomefolate, levonorgestrel, lynestrenol, medroxyprogesterone acetate, mestranol, mifepristone , misoprostol, nomegestrol acetate, norelgestromin, norethindrone, noretynodrel, norgestimate, ormeloxifene , segestersone acetate, ulipristal acetate, and any combinations thereof.

Gene Therapy and Cell Therapy

[0202] In certain embodiments, the agents described herein are combined with a gene or cell therapy regimen. Gene therapy and cell therapy include without limitation the genetic modification to silence a gene; genetic approaches to directly kill the infected cells; the infusion of immune cells designed to replace most of the patient’s own immune system to enhance the immune response to infected cells, or activate the patient’s own immune system to kill infected cells, or find and kill the infected cells; genetic approaches to modify cellular activity to further alter endogenous immune responsiveness against the infection. Examples of cell therapy include without limitation LB-1903, ENOB-HV-01, ENOB-HV-21, ENOB-HV-31, GOVX- B01, HSPCs overexpressing ALDH1 (LV-800, HIV infection), AGT103-T, and SupTl cell based therapy. Examples of dendritic cell therapy include without limitation AGS-004. CCR5 gene editing agents include without limitation SB-728T, SB-728-HSPC. CCR5 gene inhibitors include without limitation Cal-1, and lentivirus vector CCR5 shRNA/TRIM5alpha/TAR decoy- transduced autologous CD34-positive hematopoietic progenitor cells (HIV infection/HIV-related lymphoma). In some embodiments, C34-CCR5/C34-CXCR4 expressing CD4-positive T-cells are co-administered with one or more multi-specific antigen binding molecules. In some embodiments, the agents described herein are co-administered with AGT- 103 -transduced autologous T-cell therapy or AAV-eCD4-Ig gene therapy. Gene Editors

[0203] In certain embodiments, the agents described herein are combined with a gene editor, e.g., an HIV targeted gene editor. In various embodiments, the genome editing system can be selected from the group consisting of: a CRISPR/Cas9 complex, a zinc finger nuclease complex, a TALEN complex, a homing endonucleases complex, and a meganuclease complex. An illustrative HIV targeting CRISPR/Cas9 system includes without limitation EBT-101.

CAR-T Cell Therapy

[0204] In some embodiments, the agents described herein can be co-administered with a population of immune effector cells engineered to express a chimeric antigen receptor (CAR), wherein the CAR comprises an HIV antigen binding domain. The HIV antigen include an HIV envelope protein or a portion thereof, gpl 20 or a portion thereof, a CD4 binding site on gpl 20, the CD4-induced binding site on gp!20, N glycan on gpl20, the V2 of gpl20, the membrane proximal region on gp41. The immune effector cell is a T-cell or an NK cell. In some embodiments, the T-cell is a CD4+ T-cell, a CD8+ T-cell, or a combination thereof. Cells can be autologous or allogeneic. Examples of HIV CAR-T include A-1801, A-1902, convertible CAR-T, VC-CAR-T, CMV-N6-CART, anti-HIV duoCAR-T, anti-CD4 CART-cell therapy, CD4 CAR+C34-CXCR4+CCR5 ZEN T-cells, dual anti-CD4 CART-T cell therapy (CD4 CAR+C34-CXCR4 T-cells), anti-CD4 MicAbody antibody + anti-MicAbody CAR T-cell therapy (iNKG2D CAR, HIV infection), GP-120 CAR-T therapy, autologous hematopoietic stem cells genetically engineered to express a CD4 CAR and the C46 peptide.

TCR T-cell Therapy

[0205] In certain embodiments, the agents described herein are combined with a population of TCR-T-cells. TCR-T-cells are engineered to target HIV derived peptides present on the surface of virus -infected cells, for example, ImmTAV.

B-cell Therapy

[0206] In certain embodiments, the antibodies or antigen-binding fragments described herein are combined with a population of B cells genetically modified to express broadly neutralizing antibodies, such as 3BNC1 17 (Hartweger et al., J. Exp. Med. 2019, 1301 , Moffett et al., Sci. Immunol. 4, eaax0644 (2019) 17 May 2019. [0207] A compound as disclosed herein (e.g., a compound of any of Formulas I- VI) may be combined with one, two, three, or four additional therapeutic agents in any dosage amount of the compound of any of Formulas I- VI. (e.g., from 1 mg to 500 mg of compound).

[0208] In one embodiment, kits comprising a compound disclosed herein, or a pharmaceutically acceptable salt thereof, in combination with one or more (e.g., one, two, three, one or two, or one to three) additional therapeutic agents are provided.

[0209] In one embodiment, the additional therapeutic agent or agents of the kit is an antiHIV agent, selected from HIV protease inhibitors, HIV non-nucleoside or non-nucleotide inhibitors of reverse transcriptase, HIV nucleoside or nucleotide inhibitors of reverse transcriptase, HIV integrase inhibitors, HIV non-catalytic site (or allosteric) integrase inhibitors, HIV entry inhibitors, HIV maturation inhibitors, immunomodulators, immunotherapeutic agents, antibody-drug conjugates, gene modifiers, gene editors (such as CRISPR/Cas9, zinc finger nucleases, homing nucleases, synthetic nucleases, TALENs), cell therapies (such as chimeric antigen receptor T-cell, CAR-T, and engineered T cell receptors, TCR-T, autologous T cell therapies), compounds that target the HIV capsid, latency reversing agents, HIV bNAbs, immune-based therapies, phosphatidylinositol 3-kinase (P13K) inhibitors, HIV antibodies, broadly neutralizing HIV antibodies, bispecific antibodies and “antibody-like” therapeutic proteins, HIV pl7 matrix protein inhibitors, IL- 13 antagonists, peptidyl-prolyl cis-trans isomerase A modulators, protein disulfide isomerase inhibitors, complement C5a receptor antagonists, DNA methyltransferase inhibitor, HIV vif gene modulators, Vif dimerization antagonists, HIV viral infectivity factor inhibitors, TAT protein inhibitors, HIV Nef modulators, Hck tyrosine kinase modulators, mixed lineage kinase-3 (MLK-3) inhibitors, HIV splicing inhibitors, Rev protein inhibitors, integrin antagonists, nucleoprotein inhibitors, splicing factor modulators, COMM domain containing protein 1 modulators, HIV ribonuclease H inhibitors, retrocyclin modulators, CDK-9 inhibitors, dendritic ICAM-3 grabbing nonintegrin 1 inhibitors, HIV GAG protein inhibitors, HIV POL protein inhibitors, Complement Factor H modulators, ubiquitin ligase inhibitors, deoxycytidine kinase inhibitors, cyclin dependent kinase inhibitors, proprotein convertase PC9 stimulators, ATP dependent RNA helicase DDX3X inhibitors, reverse transcriptase priming complex inhibitors, G6PD and NADH-oxidase inhibitors, pharmacokinetic enhancers, HIV gene therapy, HIV vaccines, and combinations thereof.

[0210] In some embodiments, the additional therapeutic agent or agents of the kit are selected from combination drugs for HIV, other drugs for treating HIV, HIV protease inhibitors, HIV reverse transcriptase inhibitors, HIV integrase inhibitors, HIV non-catalytic site (or allosteric) integrase inhibitors, HIV entry (fusion) inhibitors, HIV maturation inhibitors, latency reversing agents, capsid inhibitors, immune-based therapies, PI3K inhibitors, HIV antibodies, and bispecific antibodies, and “antibody-like” therapeutic proteins, and combinations thereof.

[0211] In a specific embodiment, the kit includes a compound disclosed herein, or a pharmaceutically acceptable salt thereof, and an HIV nucleoside or nucleotide inhibitor of reverse transcriptase. In a specific embodiment, the kit includes a compound disclosed herein, or a pharmaceutically acceptable salt thereof, and an HIV nucleoside or nucleotide inhibitor of reverse transcriptase and an HIV non-nucleoside inhibitor of reverse transcriptase. In another specific embodiment, the kit includes a compound disclosed herein, or a pharmaceutically acceptable salt thereof, and an HIV nucleoside or nucleotide inhibitor of reverse transcriptase, and an HIV protease inhibiting compound. In an additional embodiment, the kit includes a compound disclosed herein, or a pharmaceutically acceptable salt thereof, an HIV nucleoside or nucleotide inhibitor of reverse transcriptase, an HIV non-nucleoside inhibitor of reverse transcriptase, and a pharmacokinetic enhancer. In certain embodiments, the kit includes a compound disclosed herein, or a pharmaceutically acceptable salt thereof, at least one HIV nucleoside inhibitor of reverse transcriptase, an integrase inhibitor, and a pharmacokinetic enhancer. In another embodiment, the kit includes a compound disclosed herein, or a pharmaceutically acceptable salt thereof, and two HIV nucleoside or nucleotide inhibitors of reverse transcriptase. In a specific embodiment, the kit includes a compound disclosed herein, or a pharmaceutically acceptable salt thereof, an HIV nucleoside or nucleotide inhibitor of reverse transcriptase and an HIV capsid inhibitor. In a specific embodiment, the kit includes a compound disclosed herein, or a pharmaceutically acceptable salt thereof, an HIV nucleoside inhibitor of reverse transcriptase and an HIV capsid inhibitor. In a specific embodiment, the kit includes a compound disclosed herein, or a pharmaceutically acceptable salt thereof, and an HIV capsid inhibitor. In a specific embodiment, the kit includes a compound disclosed herein, or a pharmaceutically acceptable salt thereof, and one, two, three or four HIV bNAbs. In a specific embodiment, the kit includes a compound disclosed herein, or a pharmaceutically acceptable salt thereof, one, two, three or four HIV bNAbs and an HIV capsid inhibitor. In a specific embodiment, the kit includes a compound disclosed herein, or a pharmaceutically acceptable salt thereof, one, two, three or four HIV bNAbs, an HIV capsid inhibitor, and an HIV nucleoside inhibitor of reverse transcriptase. HIV Long acting Therapy

[0212] Examples of drugs that are being developed as long acting regimens include, but are not limited to, cabotegravir, rilpivirine, any integrase LA, VM-1500 LAI, maraviroc (LAI), tenofovir implant, doravirine, raltegravir, and long acting dolutegravir. VI. Examples

Example 1. N-((S)-1-(3-(4-chloro-3-(methylsulfonamido)-l-(2,2,2-trifluo roethyl)-1H- indazol-7-yl)-6-(3-hydroxy-3-methylbut-l-yn-l-yl)pyridin-2-y l)-2-(3,5- difluorophenyl)ethyl)-2-((3bS,4aR)-5,5-difluoro-3-(trifluoro methyl)-3b,4,4a,5-tetrahydro- lH-cyclopropa[3,4]cyclopenta[l,2-c]pyrazol-l-yl)acetamide

[0213] Step 1. N-((S)-1-(3,6-dibromopyridin-2-yl)-2-(3,5-difluorophenyl)eth yl)-2-

((3bS,4aR)-5,5-difluoro-3-(trifluoromethyl)-3b,4,4a,5-tet rahydro-lH- cyclopropa[ 3,4 ]cyclopenta[ 1,2-c ]pyrazol-l -yl )acetamide

[0214] A reactor was charged with Compound A-l (200 g, 1.0 equiv.) and water (1.8 L) and the pH was adjusted to 10 by charging 2 N NaOH (15.7 g of NaOH in 358 mL of water). The mixture was charged with dichloromethane (1.6 L) and agitated contents at 20 °C for 0.5 hour. The layers were separated, and the aqueous layer was extracted with dichloromethane (800 mL). The combined organic layers were washed with 5 wt% NaCl solution (600 mL) and dried over MgSO ₄ (400 g, 2 parts). The drying agent was filtered off and washed with dichloromethane (400 mL). The filtrate was concentrated to dryness to afford (S)-l-(3,6-dibromopyridin-2-yl)-2- (3,5-difluorophenyl)ethan-l-amine free base. To a reactor was charged (5)-1-(3,6- dibromopyridin-2-yl)-2-(3,5-difluorophenyl)ethan-l-amine free base (150 g, 1.0 equiv.) and MeCN (1.5 L) followed by Compound A-2 (140.4 g, 1.3 equiv.) and triethylamine (116.2 g, 3.0 equiv.). To the mixture was charged PPACA (389.6 mL, 50 % in EtOAc, 1.6 equiv.) over 1 hour and then the mixture was agitated at 20 °C for 4 hours and then concentrated to dryness under vacuum at NMT 40 °C. The residue was diluted with EtOAc (2.3 L) and water (2.3 L) and the layers were separated. The organic layer was back- extracted with EtOAc (2.3 L). The organic layers were washed with 5 wt% aqueous NaCl solution (1.5 L) and then with aqueous NaHCO ₃ solution (1.5 L). The organic layer was concentrated to about 10 vol under vacuum at NMT 40 °C and then was slowly charged with n-heptane (3.0 L) over 1.5 hours. The slurry was agitated at 40 °C for 0.5 hour and then cooled to 20 °C and agitated for 1 hour. The solids were isolated by filtration and washed with n-heptane (750 mL). The wet cake was dried under vacuum at to afford the title compound.

[0215] Step 2. Tert-butyl (5-bromo-6-((S)-l-(2-((3bS,4aRf5,5-difluoro-3-

( trifluoromethyl )-3b,4,4a, 5 -tetrahydro- lH-cyclopropa[ 3,4]cyclopenta[ 1,2-c ]pyrazol-l- yl)acetamido)-2-(3,5-difluorophenyl)ethyl)pyridin-2-yl)carba mate [0216] A reactor wa s charged with N ((S) 1 (3,6 dibromopyridin-2-yl)-2-(3,5- difluorophenyl)ethyl)-2-((3bS,4aR)-5,5-difluoro-3-(trifluoro methyl)-3b,4,4a,5-tetrahydro-1H- cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetamide (100 g, 1.0 equiv.), Pd(OAc) ₂ (1.7 g, 5 mol%), Xantphos (13.2 g, 15 mol%), BocNH2 (21.4 g, 1.2 equiv.), and K2CO3 (42.1 g, 2.0 equiv.). The reactor was evacuated and then purged with N ₂ twice. To the mixture was charged 1,4-dioxane (700 mL) under N ₂ atmosphere. The contents were agitated at 80 °C for 22 hours and then cooled to 20 °C and diluted with EtOAc (1.0 L). The mixture was washed with water (1.0 L) and the layers were separated. The organic layer was filtered through a celite pad (50 g) and the filter cake was washed with EtOAc (500 mL). The filtrate was concentrated to dryness under vacuum and then co-evaporated with MeCN (300 mL) at NMT 40 °C to a residue. The residue was diluted with MeCN (800 mL) and water (800 mL) and the solids were then isolated by filtration, rinsing with MeCN:water (200 mL, 1:1 v/v). The solids were dried under vacuum and purified by chromatography to afford the title compound. [0217] Step 3. tert-Butyl (5-(3-amino-4-chloro-1-(2,2,2-trifluoroethyl)-1H-indazol-7-y l)- 6-((S)-1-(2-((3bS,4aR)-5,5-difluoro-3-(trifluoromethyl)-3b,4 ,4a,5-tetrahydro-1H- cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetamido)-2-(3 ,5-difluorophenyl)ethyl)pyridin- 2-yl)carbamate [0218] To a re actor were charged tert-butyl (5-bromo-6-((S)-1-(2-((3bS,4aR)-5,5- difluoro-3-(trifluoromethyl)-3b,4,4a,5-tetrahydro-1H-cyclopr opa[3,4]cyclopenta[1,2-c]pyrazol- l-yl)acetamido)-2-(3,5-difluorophenyl)ethyl)pyridin-2-yl)car bamate (180 g, 1.0 equiv.), 4- chloro-7-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-l-(2, 2,2-trifluoroethyl)-lH-indazol-3- amine (117.2 g, 1.2 equiv.), PdCh(dppf) (9.5 g, 5 mol%) and CS2CO3 (254.1 g, 3.0 equiv.). The reactor was evacuated and then back-filled twice with nitrogen. The reactor was charged with MeTHF (1260 mL) and water (360 mL) under nitrogen. The contents were agitated at 70 °C for 4 hours and then cooled to 20 °C and diluted with water (360 mL) and EtOAc (360 mL). The mixture was filtered through a celite pad (90 g) and washed with EtOAc (900 mL). The layers were separated and the aqueous phase was back-extracted with EtOAc (900 mL). The combined organic layers were dried over MgSO4 (360 g) and concentrated to dryness. The residue was purified using chromatography to afford the title compound.

[0219] Step 4. tert-Butyl (5-(4-chloro-3-(methylsulfonamido)-1-(2,2,2-trifluoroethyl)- lH-indazol-7-yl)-6-((S)-l-(2-((3bS,4aR)-5,5-difluoro-3-(trif luoromethyl)-3b,4,4a,5-tetrahydro- lH-cyclopropa[3,4]cyclopenta[l,2-c]pyrazol-l-yl)acetamido)-2 -(3,5- difluorophenyl)ethyl )pyridin-2-yl )carbamate

[0220] To a reactor was charged tert-Butyl (5-(3-amino-4-chloro-1-(2,2,2- trifluoroethyl)-lH-indazol-7-yl)-6-((S)-l-(2-((3bS,4aR)-5,5- difluoro-3-(trifluoromethyl)- 3b,4,4a,5-tetrahydro-lH-cyclopropa[3,4]cyclopenta[l,2-c]pyra zol-l-yl)acetamido)-2-(3,5- difluorophenyl)ethyl)pyridin-2-yl)carbamate (120 g, 1.0 equiv.) and MeTHF (960 mL) and the contents were cooled to 0 °C prior to charging triethylamine (91.7 g, 6 equiv.) and MsCl (52.7 g, 3.3 equiv.) at 15 C. The contents were agitated for 2 hours and then adjusted to 20 °C. The mixture was diluted with dichloromethane (960 mL) and saturated NaHCCL aqueous solution (480 mL) and the layers were separated. The aqueous layer was back-extracted with dichloromethane (480 mL) and the combined organic layers were washed with 5 wt% aqueous NaCl solution (480 mL). The organic layer was dried over Na2SO4 (180 g, 1.5 parts) and washed with dichloromethane (240 mL). The residue was concentrated to dryness and then diluted with MeTHF (960 mL) and 1 N NaOH solution (695 mL, 5.0 equiv.) and the mixture was agitated for 18 h. The mixture was cooled to 0 °C and a solution of AcOH (5.0 equiv.) in EtOAc (960 mL) was added to the contents in 0.5 h at 0 °C and the layers were separated. The organic layer was washed with 5 wt % aqueous NaCl solution (1200 mL) and the organic layer was concentrated to dryness. Purification by chromatography afforded the title compound.

[0221] Step 5. N-( (S)-l-( 6-bromo-3-(4-chloro-3-( methylsulf onamido )-l-(2,2, 2- lrijluoroelhyl)-l H-indazol-7-yl)pyridin-2-yl)-2-(3,5-difluorophenyl)elhyl)-2- ((3bS,4aR)-5,5- difluoro-3-(trifluoromethyl)-3b,4,4a,5-tetrahydro-lH-cyclopr opa[3,4]cyclopenta[l,2-c]pyrazol- 1 -yl )acetamide

[0222] Into a reactor were charged methanesulfonamide (107 g, 1.0 equiv.) and dichloromethane (214 mL) and the mixture was cooled to about 0 °C. To the contents was charged TFA (190.7 g, 15 equiv.) at about 10 °C and the contents were agitated at about 20 °C. The contents were concentrated to dryness under vacuum and diluted with dichloromethane (107 mL) and water (214 mL). The contents were adjusted to pH 7-8 by charging saturated NaHCO ₃ solution and the layers were separated. The aqueous layer was back-extracted with dichloromethane and the combined organic layers were dried over MgSO ₄ (214 g) and washed with dichloromethane (321 mL). The filtrate was concentrated under vacuum to afford a residue. The residue (75 g, 1.0 equiv.), CuBr2 (20 g, 1.0 equiv.), and CH2Br2 (488 mL) were inerted and t-BuONO (13.8 g, 1.5 equiv.) was charged at 20 °C over 15 minutes. The contents were agitated for 4 hours. The mixture was diluted with dichloromethane (750 mL) and 5 wt% aqueous citric acid solution (750 mL) and the organic layer was separated. The organic layer was washed with 5 wt % of aqueous citric acid solution (750 mL) and then concentrated under vacuum. The residue was purified by chromatography to afford the title compound. [0223] Step 6. N-((S)-1-(3-(4-chloro-3-(methylsulfonamido)-1-(2,2,2-trifluo roethyl)-1H- indazol-7-yl)-6-(3-hydroxy-3-methylbut-1-yn-1-yl)pyridin-2-y l)-2-(3,5-difluorophenyl)ethyl)-2- ((3bS,4aR)-5,5-difluoro-3-(trifluoromethyl)-3b,4,4a,5-tetrah ydro-1H- cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetamide [0224] A reactor was charged with N-((S)-1-(6-bromo-3-(4-chloro-3- (methylsulfonamido)-1-(2,2,2-trifluoroethyl)-1H-indazol-7-yl )pyridin-2-yl)-2-(3,5- difluorophenyl)ethyl)-2-((3bS,4aR)-5,5-difluoro-3-(trifluoro methyl)-3b,4,4a,5-tetrahydro-1H- cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetamide (17.0 g, 1.0 equiv.), 2-methyl-3-butyn-ol (1.7 g , 1.1 equiv.) and Pd(PPh3)2Cl2 (330.4 mg, 2.5 mol%) and inerted. To the mixture was added MeTHF (68 mL) and triethylamine (9.5 g, 5 equiv.) and the mixture was inerted. The mixture was heated at 70 °C for 5 h and an additional charge of 2-methyl-3-butyn-ol (0.3 g, 0.2 equiv.) and Pd(PPh ₃ ) ₂ Cl ₂ (132.2 mg, 1 mol%) was added, followed by heating for an additional 5 h. The contents were cooled to 20 ^° C and diluted with EtOAc (102 mL) and water (102 mL). The organic layer was separated and concentrated under vacuum to a residue. The residue was purified by chromatography to afford the title compound. HRMS (ESI): m/z calculated for C ₃₈ H ₃₁ ClF ₁₀ N ₇ O ₄ S ([M+Na] ⁺ ) 906.16816, found 906.17194.

Example 2. N-((S)-1-(3-(4-chloro-3-(methylsulfonamido)-1-(2,2,2-trifluo roethyl)-lH- indazol-7-yl)-6-(3-methylbut-3-en-l-yn-l-yl)pyridin-2-yl)-2- (3,5-difluorophenyl)ethyl)-2- ((3bS,4aR)-5,5-difluoro-3-(trifluoromethyl)-3b,4,4a,5-tetrah ydro-lH- cyclopropa[3,4]cyclopenta[l,2-c]pyrazol-l-yl)acetamide

[0225] Step 1. (S)-1-(3-bromo-6-(3-methylbut-3-en-l-yn-l-yl)pyridin-2-yl)-2 -(3,5- difluorophenyl )ethan-l -amine

[0226] To a 1 L of 4-neck flask equipped with a condenser, charged Compound A-1 (50.0 g, 1.0 equiv.) and Pd(PPh3)2Cl ₂ (6.2 g, 0.1 equiv.). The reactor was evacuated under vacuum then purged with N ₂ . The reactor was charged with MeTHF (400 mL), triethylamine (44.8 g, 5.0 equiv.), and isopropenylacetylene (8.8 g, 1.5 equiv.) under N2. The contents were heated to 77 °C and agitated for 5 hours under N2 to give a brown slurry. The contents were cooled 20 °C, then solids were filtered off and washed with MeTHF (200 mL). The organic filtrate was washed with water (300 mL) and dried over MgSO ₄ (50 g, 1 part). The drying agent was filtered off and was washed with EtOAc (200 mL). The filtrate was concentrated under vacuum at 40 °C and the residue was purified by chromatography (Eluent: 65% EtOAc in n- hexane, Rf = 0.4) to provide the title compound.

[0227] Step 2. N-((S)-l-(3-bromo-6-(3-methylbut-3-en-l-yn-l-yl)pyridin-2-yl )-2-(3,5- difluorophenyl)ethyl)-2-((3bS,4aR)-5,5-difluoro-3-(trifluoro methyl)-3b,4,4a,5-tetrahydro-lH- cyclopropa[ 3,4 ]cyclopenta[ 1,2-c ]pyrazol-l -yl )acetamide

[0228] A reactor was charged with (S)-l-(3-bromo-6-(3-methylbut-3-en-l-yn-l- yl)pyridin-2-yl)-2-(3,5-difluorophenyl)ethan-l-amine (16.5 g, 1.0 equiv.), 2-((3bS,4aR)-5,5- difluoro-3-(trifluoromethyl)-3b,4,4a,5-tetrahydro-lH-cyclopr opa[3,4]cyclopenta[l,2-c]pyrazol- l-yl)acetic acid (13.6 g, 1.1 equiv.), and MeCN (115 mL), followed by triethylamine (10.2 g, 2.3 equiv.). To the mixture was charged PPACA (50% in DMF, 41.8 g, 1.5 equiv.) over 20 minutes 25 °C. The contents were a thick slurry. Additional MeCN (149 mL) was charged to improve agitation. The contents were agitated at 20 °C for 1 hour and then diluted with purified water (165 mL) and dichloromethane (660 mL). The contents were agitated at ambient temperature for 10 minutes until all solids were dissolved. The layers were separated, and the organic layer was washed with saturated NaHCCL solution (165 mL). The organic layer was dried over MgSOr (33 g, 2 parts), which was filtered off and washed with dichloromethane (83 mL). The filtrate was concentrated under vacuum at 40 °C. To the residue (pale brown solids) was charged EtOAc (50 mL) and n -heptane (165 mL). The resulting slurry was agitated at 0 °C for 2 hours and filtered, washing the cake with cooled ElOAc/n-heplane (1:5 v/v, 66 mL). The solids were dried under vacuum at 30 °C overnight to afford the title compound. [0229] Step 3. N-((S)- l-(3-(3-amino-4-chloro-l-(2,2,2-trifluoroethyl)-l H-indazol-7-yl)- 6-(3-methylbut-3-en-l-yn-l-yl)pyridm-2-yl)-2-(3,5-difluoroph enyl)ethyl)-2-((3bS,4aR)-5,5- difluoro-3-( trifluoromethyl)-3b, 4, 4a, 5-tetrahydro- lH-cyclopropa[3, 4] cyclopenta[ l,2-c]pyrazol- 1 -yl )acetamide

[0230] A reactor was charged with N-((S)-l-(3-bromo-6-(3-methylbut-3-en-l-yn-l- yl)pyridin-2-yl)-2-(3,5-difluorophenyl)ethyl)-2-((3bS,4aR)-5 ,5-difluoro-3-(trifluoromethyl)- 3b,4,4a,5-tetrahydro-lH-cyclopropa[3,4]cyclopenta[l,2-c]pyra zol-l-yl)acetamide (17.0 g, 1.0 equiv.), 4-chloro-7-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-l-( 2,2,2-trifluoroethyl)-lH- indazol-3-amine (14.9 g, 1.5 equiv.), PdCl ₂ (235 mg, 5 mol%), CyPPh2 (711 mg, 10 mol%), and KHCO3 (14.9 g, 3.0 equiv.) and was evacuated and back-filled with N2 three times. The reactor was charged with MeTHF (250 mL) and water (62.5 mL) and the contents were evacuated and then purged with N2 for 5 minutes. The contents were agitated 70 °C for 16 hours under N2 flow and then cooled to 25 °C and filtered through a Celite pad, which was washed with EtOAc. The filtrate was washed with water and 10 wt% aqueous NaCl solution. The organic layer was dried over MgSCh, filtered, and washed with EtOAc, and concentrated to dryness under vacuum. The residue was purified by chromatography (Eluent: 20% EtOAc in n-hexane, Rf = 0.2) to afford the title compound.

[0231] Step 4. N-((S)-1-(3-(4-chloro-3-(methylsulfonamido)-1-(2,2,2-trifluo roethyl)-1H- indazol-7-yl)-6-(3-methylbut-3-en-1-yn-1-yl)pyridin-2-yl)-2- (3,5-difluorophenyl)ethyl)-2- ((3bS,4aR)-5,5-difluoro-3-(trifluoromethyl)-3b,4,4a,5-tetrah ydro-1H- cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetamide 5 [0232] To a reactor was charged N-((S)-1-(3-(3-amino-4-chloro-1-(2,2,2-trifluoroethyl)- 1H-indazol-7-yl)-6-(3-methylbut-3-en-1-yn-1-yl)pyridin-2-yl) -2-(3,5-difluorophenyl)ethyl)-2- ((3bS,4aR)-5,5-difluoro-3-(trifluoromethyl)-3b,4,4a,5-tetrah ydro-1H- cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetamide (18.0 g, 1.0 equiv.) and MeTHF (180 10 mL) under inert conditions. The mixture was cooled to below 5 °C and triethylamine (13.5 g, 6 equiv.) was charged followed by MsCl (7.6 g, 2.5 equiv.) over 15 minutes. After 2 hours, the reaction was quenched with water (180 mL water) and extracted with EtOAc (90 mL). The aqueous layer was back-extracted with EtOAc (90 mL). The organic layers were combined, washed with 5 wt% NaCl solution (90 mL), and concentrated to dryness at 40 °C under vacuum. 15 To the residue was charged (180 mL MeTHF) and the contents were adjusted to 30 – 35 °C. The solution was charged with 1 N NaOH aqueous solution (2.7 g of NaOH, 68 mL, 3.0 equiv.) and the mixture was agitated at 35 °C for 7 hours. The mixture was adjusted to 20 °C and was diluted with 1 N AcOH solution and 90 mL EtOAc. After agitation at 20 - 25 °C for 30 minutes, the organic layer was isolated and washed with 90 mL of 5 wt% of aqueous NaCl solution. The 20 organic layer was concentrated under vacuum at NMT 45 °C and purified by chromatography to afford the title compound. HRMS (ESI): m/z calculated for C38H29ClF10N7O3S ([M+H] ⁺ ) 888.15759, found 888.15859. Example 3. N-((S)-1-(3-(4-chloro-3-(methylsulfonamido)-1-(2,2,2-trifluo roethyl)-1H- indazol-7-yl)-6-(3-methylbut-1-yn-1-yl)pyridin-2-yl)-2-(3,5- difluorophenyl)ethyl)-2- ((3bS,4aR)-5,5-difluoro-3-(trifluoromethyl)-3b,4,4a,5-tetrah ydro-1H- cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetamide [0233] Step 1. (S)-1-(3-bromo-6-(3-methylbut-1-yn-1-yl)pyridin-2-yl)-2-(3,5 - difluorophenyl)ethan-1-amine [0234] To a pressure vessel was added Compound A-1 (5 g, 1 equiv.), 3-methyl-1- butyne (2 equiv.), triethylamine (5 equiv.), Pd(PPh ₃ ) ₂ Cl ₂ (0.11 equiv.), and 2- methyltetrahydrofuran (5 v/w). The mixture was stirred at room temperature for 15 minutes with purging with nitrogen. The reaction mixture was sealed and heated to 65 °C, agitating for 72 hours. The mixture was cooled to room temperature and water (30 mL) was added. The layers were separated and the organic layer was washed with 3M NaOH (20 mL), brine (10 mL), dried over sodium sulfate, then filtered. The solution was concentrated to dryness. The crude was purified by column chromatography, using a 0 – 50% EtOAc in heptane containing 1% triethylamine. The fractions containing product were combined and concentrated to obtain the title compound. [0235] Step 2. N-((S)-1-(3-bromo-6-(3-methylbut-1-yn-1-yl)pyridin-2-yl)-2-( 3,5- difluorophenyl)ethyl)-2-((3bS,4aR)-5,5-difluoro-3-(trifluoro methyl)-3b,4,4a,5-tetrahydro-1H- cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetamide [0236] To a flask was added (S)-1-(3-bromo-6-(3-methylbut-1-yn-1-yl)pyridin-2-yl)-2- (3,5-difluorophenyl)ethan-1-amine (0.83 g, 1 equiv.), 2-((3bS,4aR)-5,5-difluoro-3- (trifluoromethyl)-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyc lopenta[1,2-c]pyrazol-1-yl)acetic acid (1.3 equiv.), triethylamine (2.5 equiv.) and acetonitrile (7 v/w). The mixture was stirred at room temperature for 15 minutes with purging with nitrogen. To the mixture was charged PPACA (50% in EtOAc, 1.5 equiv.) over 18 hours at room temperature. The reaction mixture colour changed from orange to red, then a precipitate appeared. The mixture was concentrated to dryness then EtOAc (50 mL) and water (100 mL) were added. The layers were separated, the organic layer was washed with brine (50 mL), dried over sodium sulfate, then filtered. TLC on the mixture showed no remaining starting material. The crude was purified by column chromatography, using a 0 – 50% EtOAc in heptane containing 1% triethylamine. The fractions containing product were combined and concentrated to obtain the title compound.

[0237] Step 3. N-((S)-1-(3-(3-amino-4-chloro-1-(2,2,2-trifluoroethyl)-1H-in dazol-7-yl)- 6-(3-methylbut-1-yn-1-yl)pyridin-2-yl)-2-(3,5-difluorophenyl )ethyl)-2-((3bS,4aR)-5,5-difluoro-3- (trifluoromethyl)-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyc lopenta[1,2-c]pyrazol-1- yl)acetamide [0238] To a flask was added N-((S)-1-(3-bromo-6-(3-methylbut-1-yn-1-yl)pyridin-2-yl)- 2-(3,5-difluorophenyl)ethyl)-2-((3bS,4aR)-5,5-difluoro-3-(tr ifluoromethyl)-3b,4,4a,5- tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)a cetamide (0.5 g, 1.0 equiv.), 4- chloro-7-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-(2, 2,2-trifluoroethyl)-1H-indazol-3- amine (1.3 equiv.), palladium dichloride (0.05 equiv.), cyclohexyldiphenylphosphine (0.09 eq) and KHCO3 (3.0 equiv.) and 2-MeTHF (8 v/w). The system was purged by bubbling nitrogen through the mixture for 2 minutes. The mixture was heated to 70 °C while agitating for 18 hours. UPLC analysis showed 64.2% of the desired product with 3.4% of an allene impurity. The reaction mixture was cooled to room temperature, filtered through a Celite plug (1.0 g), washing the Celite bed with ethyl acetate (10 mL). The collected organic solution was washed with water (10 mL), brine (10 mL), and then dried over sodium sulfate. The solution was concentrated to dryness and combined with another lot of crude material. The crude was purified by column chromatography, using a 0 – 50% EtOAc in heptane containing 1% triethylamine. The fractions containing product were combined and concentrated to obtain the title compound.

[0239] Step 4. N-((S)-1-(3-(4-chloro-3-(methylsulfonamido)-1-(2,2,2-trifluo roethyl)-1H- indazol-7-yl)-6-(3-methylbut-1-yn-1-yl)pyridin-2-yl)-2-(3,5- difluorophenyl)ethyl)-2-((3bS,4aR)- 5,5-difluoro-3-(trifluoromethyl)-3b,4,4a,5-tetrahydro-1H-cyc lopropa[3,4]cyclopenta[1,2- c]pyrazol-1-yl)acetamide [0240] To a flask was added N-((S)-1-(3-(3-amino-4-chloro-1-(2,2,2-trifluoroethyl)-1H- indazol-7-yl)-6-(3-methylbut-1-yn-1-yl)pyridin-2-yl)-2-(3,5- difluorophenyl)ethyl)-2- ((3bS,4aR)-5,5-difluoro-3-(trifluoromethyl)-3b,4,4a,5-tetrah ydro-1H- cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetamide (0.9 g, 1 equiv.), triethylamine (5 equiv.), and 2-MeTHF (20 v/w) and allowed to stir for 15 minutes while cooled using an ice bath. Methanesulfonyl chloride (2.5 equiv.) was added dropwise over 5 minutes and the ice bath was removed, allowing the mixture to stir for 3 hours. TLC confirmed no starting material remained. Water (20 mL) was charged to dissolve salts, the layers were separated, and the organic layer was washed with brine (25 mL). The organic layer was dried over sodium sulfate, filtered, and concentrated to dryness to obtain 1.3 g of crude material. Analysis by UPLC show full conversion of starting material with 92% purity of the bis-mesylate. The crude intermediate was dissolved in 2-MeTHF (5 v/w), 1 M NaOH was added (5 v/w), and the reaction mixture was heated to 30 °C for 18 hrs with agitation. The crude was again redissolved in 2-MeTHF (10 v/w), 1 M NaOH was added (10 v/w), and the reaction mixture was heated to 35 °C for 18 hrs with agitation after which UPLC showed 94% purity of the desired product. After cooling the layers separated and the organic layer was washed with acetic acid (10 v/w), then water (10 mL), then brine (10 mL). The organic layer was dried over sodium sulfate, filtered, and concentrated to dryness to give 1.1. g of crude product at 94% purity. The crude was purified by column chromatography, using a 0 – 50% EtOAc in heptane containing 1% triethylamine. The fractions containing product were combined and concentrated to obtain the title compound. LRMS (ESI): m/z calculated for C ₃₈ H ₃₀ ClF ₁₀ N ₇ O ₃ SNa ([M+Na] ⁺ ) 912.16, found 912.22. Example 4. N-((S)-1-(3-(4-chloro-3-(N-methylmethylsulfonamido)-1-(2,2,2 -trifluoroethyl)- 1H-indazol-7-yl)-6-(3-methyl-3-(methylsulfonyl)but-1-yn-1-yl )pyridin-2-yl)-2-(3,5- difluorophenyl)ethyl)-2-((3bS,4aR)-5,5-difluoro-3-(trifluoro methyl)-3b,4,4a,5-tetrahydro- 1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetamide [0241] A reactor was charged with lenacapavir sodium (14.5 g, 1.0 equiv.), DMF (145 mL), and iodomethane (6.2 g, 3.0 equiv.). Contents were heated to 40 °C and agitated for 6 hours. After 5 hours, the contents were diluted with MTBE (740 mL) and washed with purified water (290 mL) three times. The organic layer was concentrated under vacuum, and further dried to obtain the title compound. HRMS (ESI): m/z calculated for C40H35ClF10N7O5S2 ([M+H] ⁺ ) 982.16644, found 982.16587.

Example 5.2-((3bS,4aR)-5,5-difluoro-3-(trifluoromethyl)-3b,4,4a,5-te trahydro-1H- cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)-N-((S)-2-(3,5- difluorophenyl)-1-(6-(3- methyl-3-(methylsulfonyl)but-1-yn-1-yl)-3-(3-(methylsulfonam ido)-1-(2,2,2-trifluoroethyl)- 1H-indazol-7-yl)pyridin-2-yl)ethyl)acetamide [0242] Step 1. N-((S)-1-(3-(3-amino-1-(2,2,2-trifluoroethyl)-1H-indazol-7-y l)-6-(3- methyl-3-(methylsulfonyl)but-1-yn-1-yl)pyridin-2-yl)-2-(3,5- difluorophenyl)ethyl)-2-((3bS,4aR)- 5,5-difluoro-3-(trifluoromethyl)-3b,4,4a,5-tetrahydro-1H-cyc lopropa[3,4]cyclopenta[1,2- c]pyrazol-1-yl)acetamide [0243] To a flask were added N-((S)-1-(3-bromo-6-(3-methyl-3-(methylsulfonyl)but-1- yn-1-yl)pyridin-2-yl)-2-(3,5-difluorophenyl)ethyl)-2-((3bS,4 aR)-5,5-difluoro-3- (trifluoromethyl)-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyc lopenta[1,2-c]pyrazol-1- yl)acetamide (2.6 g, 1.0 equiv.), 7-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-(2,2,2- trifluoroethyl)-1H-indazol-3-amine (1.6 g, 1.3 equiv.), dichlorobis(tricyclohexylphosphine)palladium(II) (0.16 g, 0.03 equiv.), and KHCO ₃ (1.08 g, 3.0 equiv.). The system was purged with N2 for 15 minutes. The flask was charged with i-PrOAc (20.8 mL) and H ₂ O (5.2 mL) and degassed with N ₂ for 20 minutes. The mixture was stirred at 83 °C for 16 hours. The reaction mixture was cooled to 40 °C and H2O (13 mL) were added. The reaction mixture was agitated for 10 minutes and the layers were separated. The aqueous layer was extracted with i-PrOAc (3 × 13 mL). The organic layers were combined and concentrated under reduced pressure to obtain the crude material. The crude material was purified by chromatography, eluting with an EtOAc in heptane gradient (40 to 50%), to afford the title compound. [0244] Step 2.2-((3bS,4aR)-5,5-difluoro-3-(trifluoromethyl)-3b,4,4a,5-te trahydro-1H- cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)-N-((S)-2-(3,5- difluorophenyl)-1-(6-(3-methyl-3- (methylsulfonyl)but-1-yn-1-yl)-3-(3-(methylsulfonamido)-1-(2 ,2,2-trifluoroethyl)-1H-indazol-7- yl)pyridin-2-yl)ethyl)acetamide [0245] To a reactor was charged N-((S)-1-(3-(3-amino-1-(2,2,2-trifluoroethyl)-1H- indazol-7-yl)-6-(3-methyl-3-(methylsulfonyl)but-1-yn-1-yl)py ridin-2-yl)-2-(3,5- difluorophenyl)ethyl)-2-((3bS,4aR)-5,5-difluoro-3-(trifluoro methyl)-3b,4,4a,5-tetrahydro-1H- cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetamide (90 g, 105 mmol), 2-MeTHF (900 mL), and triethylamine (73 mL, 5 equiv.), and the mixture was cooled to 0 - 5 °C. To the cold mixture was charged methanesulfonyl chloride (20.4 mL, 2.5 equiv.) at about 10 °C. The reaction was stirred for 4 hours and then concentrated to an oil and dissolved in 2-MeTHF (900 mL). The resulting solution was washed with saturated NaHCO3 (900 mL). To the organic layer was charged 1 M NaOH (270 mL) and the resulting solution was agitated overnight at 35 °C. The resulting biphasic solution was separated, and the top organic layer was washed with 1 M AcOH (270 mL), followed by 10% aqueous NaCl solution (450 mL). The organic layer was dried over MgSO ₄ , filtered, and the filtrate was concentrated to a solid. The crude product was adsorbed onto 90 g of silica gel using dichloromethane, and loaded onto a silica gel column (900 g). The column was eluted with 0 - 30% EtOAc in dichloromethane gradient. The product fractions were combined and concentrated to obtain the title compound. HRMS (ESI): m/z calculated for C ₃₉ H ₃₄ F ₁₀ N ₇ O ₅ S ₂ ([M+H] ⁺ ) 934.18977, found 934.18909. Example 6. N-((S)-1-(3-(4-chloro-3-(N-ethylmethylsulfonamido)-1-(2,2,2- trifluoroethyl)- 1H-indazol-7-yl)-6-(3-methyl-3-(methylsulfonyl)but-1-yn-1-yl )pyridin-2-yl)-2-(3,5- difluorophenyl)ethyl)-2-((3bS,4aR)-5,5-difluoro-3-(trifluoro methyl)-3b,4,4a,5-tetrahydro- 1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetamide [0246] To a flask was charged lenacapavir sodium (15.0 g, 1.0 equiv., 15.13 mmol), DMF (150 mL), and EtI (1.58 mL, 1.3 equiv.). The reaction was stirred at ambient temperature overnight and then diluted with MTBE (750 mL) and washed with 3 ×180 mL water. The organic layer was washed with brine (375 mL). The organic layer was concentrated to a crude foam, dissolved in dichloromethane, and purified using chromatography with a 0 - 100% EtOAc in heptanes gradient. The fractions containing product were combined and concentrated to obtain the title compound. HRMS (ESI): m/z calculated for C ₄₁ H ₃₇ ClF ₁₀ N ₇ O ₅ S ₂ ([M+H] ⁺ ) 996.18209, found 996.18380. VII. Biological Examples [0247] The antiviral properties of a compound of the invention may be determined using Test A described below. Test A: Antiviral assay in the human MT-4 T-lymphoblastoid cell line [0248] For the MT-4 antiviral assay, 50 μL of 3-fold serially diluted compound in complete RPMI medium was added to each well of a 384-well plate (10 concentrations) in quadruplicate. MT-4 cells were infected with HIV-1 (IIIb strain) at a multiplicity of infection (m.o.i.) of ~0.005 for 1 hour at 37°C and 20 μL of virus/cell mixture (~2,000 cells) was added to each well of the assay plate containing 50 μL of diluted compound. A positive control (1 µM azidothymidine, AZT) and a negative control (dimethyl sulfoxide, DMSO) were included in every assay plate to define 100% and 0% protection, respectively. The final DMSO concentration in the assay was 0.5%. The plates were then incubated at 37°C for 5 days. At the end of the incubation, 30 μL of CellTiter-Glo reagent (Promega Madison, WI) was added to each well of the assay plates. Cell lysis was carried out by incubating the assay plates at room temperature for 10 minutes followed by the quantification of chemiluminescence signal using an EnVision plate reader (Perkin Elmer, Shelton, CT). Antiviral dose response data were normalized to positive and negative controls in each plate and analyzed by curve fitting after conversion of the data to % cell death to determine the half-maximal effective concentration (EC50) value, defined as the compound concentration that caused a 50% protection from cytopathic effect (CPE)-dependent virus-induced cell death. Test B: Cytotoxicity assay in MT-4 cells [0249] Compound cytotoxicity and the corresponding half-maximal cytotoxicity concentration (CC50) values was determined using the same protocol as described in the antiviral assay (Test A) except that uninfected cells were used and the data were normalized to the 100% viability control (DMSO) wells on each plate. [0250] Compounds of the present invention demonstrate potent antiviral activity (Test A) and low cytotoxicity (Test B) in the MT-4 cell line as depicted in the table below. Example Antiviral Activity, Cytotoxicity, No. MT-4 EC50 (nM) MT-4 CC50 (nM) 1 0.34 3,610 2 18 8,743 3 21 7,505 4 8.3 >50,000 5 0.07 9,484 6 3.3 >50,000 [0251] All references, including publications, patents, and patent documents are incorporated by reference herein, as though individually incorporated by reference. The present disclosure provides reference to various embodiments and techniques. However, it should be understood that many variations and modifications may be made while remaining within the spirit and scope of the present disclosure.